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Résumé 
Contexte 
L’occlusion d’une artère du cœur cause un syndrome coronarien aigu (SCA) soit avec 
une élévation du segment ST (IAMEST) ou sans élévation du segment ST (1).  Le 
traitement des patients avec un IAMEST requiert soit une intervention coronarienne 
d’urgence (ICP primaire) ou une thérapie fibrinolytique (FL). La thérapie FL peut être 
administrée soit dans un contexte pré-hospitalier (PHL) ou à l’hôpital. Une prise en charge 
précoce des patients avec SCA peut être améliorée par un simple indice de risque.  
Objectifs 
Les objectifs de cette thèse  étaient de : 1) comparer l’ICP primaire et la thérapie FL 
(2); décrire plusieurs systèmes internationaux de PHL;  (3) développer et valider un indice 
de risque simplifié pour une stratification précoce des patients avec SCA.  
Méthodes 
Nous complétons des méta-analyses, de type hiérarchique Bayésiennes portant sur 
l’effet de la randomisation, d’études randomisées et observationnelles; complétons 
également un sondage sur des systèmes internationaux de PHL; développons et validons un 
nouvel indice de risque pour ACS (le C-ACS). 
Résultats 
Dans les études observationnelles, l’ICP primaire, comparée à la thérapie FL, est 
associée à une plus grande réduction de la mortalité à court-terme; mais ce sans bénéfices 
concluants à long terme. La FL pré-hospitalière peut être administrée par des professionnels 
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de la santé possédant diverses  expertises. Le C-ACS a des bonnes propriétés 
discriminatoires et pourrait être utilisé dans la stratification des patients avec SCA.  
Conclusion 
Nous avons comblé plusieurs lacunes importantes au niveau de la connaissance 
actuelle. Cette thèse de doctorat contribuera à améliorer l’accès à des  soins de qualité 
élevée  pour les patients ayant un  SCA. 
Mots clés français 
Infarctus du myocarde, Intervention coronarienne percutanée, Indice de risque, Thérapie 
fibrinolytique, Syndrome coronariens aigu, Méta-analyse, Thérapie de reperfusion, Service 
médicale pré-hospitalier. 
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Summary 
Background 
Acute occlusion of an artery of the heart results in acute coronary syndromes 
(ACS), either with ST-segment elevation (STEMI) or without ST-segment elevation (1). 
STEMI requires urgent treatment to restore coronary artery flow either by primary 
percutaneous coronary intervention (PCI) or fibrinolytic therapy (FL) (2).  Although several 
randomized controlled trials (RCTs)  demonstrate the superiority of primary PCI in 
reducing mortality compared to FL (2), the benefit of primary PCI over FL remains 
uncertain in unselected “real-life” patients (3,4).  
FL can be administered either in the pre-hospital setting (i.e., pre-hospital FL 
(PHL)) or at the hospital. PHL is rarely available outside Europe (5,6).  Insights into the 
organization of PHL systems of care may promote more widespread use of PHL. 
Risk stratification of ACS patients should be prompt to ensure timely PCI for high-
risk patients and to avoid unnecessary intervention in low-risk patients (7).  Despite the 
availability of numerous ACS risk scores, there is still no simple risk score that can be 
easily applied in the initial management of ACS patients (8).  
Objectives 
The objectives of this doctoral dissertation were to address these current knowledge 
gaps in the optimal management of ACS. The objectives were to: 1) evaluate the efficacy, 
effectiveness, and safety of primary PCI and FL, (2) describe the infrastructure, processes 
and outcomes of several international PHL systems; and (3) develop and validate a novel 
clinical risk score for early risk stratification of ACS patients.   
Methods 
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To address these objectives, I completed Bayesian hierarchical random-effects meta-
analyses of published RCTs and observational studies which compare primary PCI and FL 
in patients with STEMI.  I undertook a survey of the infrastructure, processes and outcomes 
of PHL in several European and North American pre-hospital emergency systems.  Finally, 
I developed and validated an ACS risk score called the Canadian ACS (C-ACS). 
Results 
Primary PCI was superior to FL in reducing short-term mortality in RCTs and 
observational studies.  However, the long-term survival benefit of primary PCI was noted 
only in RCTs, and not in the observational studies. PHL can be effectively delivered by 
health care professionals with variable levels of expertise. The new risk score, C-ACS, has 
good discriminant properties for short- and long-term mortality in patients with ACS. 
Conclusions 
 The first manuscript of this dissertation has been recognized as one of the most 
valuable recent publications in STEMI management and has contributed to reorganization 
of STEMI care in Ontario.  The other two manuscripts in this dissertation provide 
practical information and tools for health professionals caring for patients with ACS.  In 
summary, this doctoral dissertation has and will continue to contribute to improve access 
to high quality care for patients with ACS.  
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Chapter 1. 
Introduction 
Cardiovascular diseases (CVD) are the leading causes of mortality worldwide (9) and 
the global CVD burden is enormous (9-10). As developing countries undergo 
epidemiologic transition from infectious to chronic diseases, the potential global burden of 
CVD mortality and morbidity is immense (11). One of the most common CVDs is acute 
coronary syndrome (ACS), which occurs secondary to acute total or partial occlusion of an 
artery that supplies blood to the heart (i.e., a coronary artery) by a blood clot (11). There 
are, among others, three critical issues related to ACS care that remain unresolved and are 
the focus of this dissertation.  The following paragraphs describe each of these three issues. 
 Do the benefits of PCI over FL observed in RCTs extend to “real-‘life” patients? 
Acute myocardial infarction (AMI) with ST-segment elevation (STEMI) is a frequent 
and highly lethal type of ACS (2).  STEMI occurs secondary to acute total occlusion of a 
coronary artery.  Complete lack of blood flow will lead to irreversible cell death in the 
affected part of the heart. Management of STEMI requires urgent reperfusion therapy (RT) 
which restores blood flow in the occluded coronary artery (2).   
  RT can be provided either by the administration of FL medication which dissolves the 
blood clot, or by primary percutaneous coronary intervention (PCI) which involves the 
insertion of a catheter into the coronary artery to break up the blood clot (2).  Twenty-six 
randomized clinical trials (RCT) (12-37) have reported survival benefit of primary PCI over 
FL in patients with STEMI.  However, it remains unclear whether the survival benefit of 
primary PCI over FL can be replicated in “real-life” patients (3-4). Even though RCTs are 
generally considered the “gold standard” studies to evaluate the efficacy of interventions, 
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the benefits of complex interventions in “ideal” patients under “ideal” conditions may not 
be replicable in sicker, “real-life” patients in less than “ideal” conditions (38-39).  The first 
knowledge gap addressed in this doctoral dissertation relates to whether or not the 
superiority of primary PCI over FL can be confirmed in unselected “real-life” patients. 
Can PHL systems of care be implemented successfully outside Europe? 
Pre-hospital administration of fibrinolytic therapy (PHL) improves survival compared 
to in-hospital administration of FL in patients with STEMI (40).  However, due to the 
complexity of the pre-hospital emergency medical systems (EMS) required for PHL, this 
RT strategy is rarely available outside Europe (5-6).  The second knowledge gap, addressed 
in this doctoral dissertation, relates to whether or not PHL can be administered by health 
care professionals with different expertises. Insights from successful PHL programs may 
allow more widespread implementation of PHL. 
Can a new risk score discriminate high-risk ACS patients? 
Despite the availability of several risk scores (40-64), there is no ideal risk score that 
can be used for rapid pre-hospital risk stratification of ACS patients (65).   Prompt and 
accurate pre-hospital identification of high-risk ACS patients may guide early management 
of these patients including selection of the most appropriate hospital for them. The third 
knowledge gap, addressed in this doctoral dissertation, relates to whether a novel and 
simple risk score can be used for early risk stratification of ACS patients. 
         The objectives of the three manuscripts that comprise this dissertation are: (1) To 
compare the efficacy, effectiveness, and safety of primary PCI and FL for STEMI patients 
in RCTs and observational studies; (2) To describe the infrastructures, processes and 
outcomes of PHL in several international jurisdictions, and (3) To develop and validate a 
risk score for early pre-hospital risk stratification of ACS patients. 
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Structure of the thesis 
 
 The thesis is structured as follows: following an introduction in Chapter 1, the 
literature review in Chapter 2 is divided into four sections: 1) burden, pathophysiology and 
management of different types of ACS; 2) efficacy, effectiveness and safety of RT; 3) pre-
hospital management of ACS and 4) risk stratification of patients with ACS.  In Chapter 3, 
the objectives and research hypotheses of this doctoral dissertation are presented.  In 
chapters 4-6, I describe the rationale, methodology and results of my work in three 
manuscripts, as followed: 
• The first manuscript presented in Chapter 4 is entitled: “Comparison of Primary 
Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment Elevation 
Myocardial Infarction – Bayesian Hierarchical Meta-Analyses of Randomized Controlled 
Trials and Observational Studies.”   This manuscript was presented at the American Heart 
Association Congress in 2007.  It was published in Circulation in 2009 (66), (impact factor 
of the journal: 14.7 in year 2012). 
• The second manuscript presented in Chapter 5 is entitled: “The pre-hospital fibrinolysis 
experience in Europe and North America and implications for wider dissemination”.  This 
manuscript was published in the Journal of the American College of Cardiology – 
Intervention in 2011 (67), (impact factor: 6.8 in year 2012). 
•   Finally, the third manuscript presented in Chapter 6 is entitled “C-ACS:  A New Risk 
Score for Early Prognostication in Acute Coronary Syndromes”.  This manuscript has been 
presented at the American Heart Association Congresses in 2007 and 2010 and is currently 
in press at the American Heart Journal (impact factor: 4.8 in 2012) 
 In Chapter 7, I discuss the results of the research undertaken in this doctoral 
dissertation including its limitations and strengths.  I expand on the implications of the 
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findings in terms of cardiovascular care in Quebec and finally conclude on future research 
directions. 
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Chapter 2 
Literature review 
Introduction 
 Cardiovascular diseases (CVDs) are the leading cause of death in every region of 
the world except sub-Saharan Africa (9-11).  Within a few years, even in sub-Saharan 
Africa, CVDs mortality will exceed mortality related to infectious diseases (11).  Although 
CVD has traditionally been thought of as a disease of affluent populations, urbanization and 
industrialization have resulted in the increased prevalences of several detrimental lifestyle 
habits (i.e., tobacco use, physical inactivity, sedentary behavior, and unhealthy nutrition) in 
developing countries.  As developing countries undergo epidemiologic transition from 
infectious to chronic degenerative disease, the worldwide burden of CVD mortality will 
become enormous (11).  
 In the following literature review, I expand on the burden of CVD, the 
pathophysiology of CVD, the types of ischemic heart diseases, the management of acute 
myocardial infarction (AMI) and the importance of time delays to treatment.  I also 
describe the infrastructure and functioning of several Canadian and international systems of 
AMI care, as well as the outcomes of patients with acute coronary syndromes (ACS) 
managed by these systems of care. 
2.2      Pathophysiology of CVD  
 CVD comprises a wide range of cardiac, vascular (i.e., diseases of the vessels and 
cerebro-vascular diseases (i.e., diseases of the vessels that supply blood to the brain) (11).  
The most common cardiac diseases include ischemic heart diseases (i.e., diseases of the 
vessels that supply blood to the heart), congestive heart failure (i.e., weakness of the heart 
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muscle) and valvular heart diseases (i.e., diseases of the valves that separate the chambers 
of the heart) (11).   
 Ischemic heart disease is secondary to acute or chronic total or partial blockage of 
an artery supplying blood to the heart (i.e., a coronary artery) (11).  Acute coronary 
syndromes (ACS) are conditions with acute blockage of the coronary artery.  If the 
remaining blood supply is sufficient to maintain viability of the heart muscle, the acute 
blockage of the coronary artery results in unstable angina (68).  If the blood supply is 
inadequate to maintain viability of the heart muscle, it results in acute myocardial infarction 
(AMI) (66). Acute total occlusion of the coronary artery results in ST-segment elevation 
AMI (STEMI) (1), while acute partial occlusion of the coronary artery induces an AMI 
without ST-segment elevation (NSTEMI) (68). STEMI is highly lethal and must be treated 
promptly (1-2).  Since the management and prognosis of NSTEMI and unstable angina are 
similar, these syndromes are categorized together as ACS without ST-segment elevation 
(NSTE-ACS) (68).  
 Differentiation of STEMI and NSTEMI requires recognition of ST-segment 
elevation on the electrocardiogram (ECG) (68).  An ECG is a test that evaluates the blood 
supply to the heart by positioning skin electrodes on the chest wall (69).  The test is non-
invasive, painless and requires approximately five minutes (69).   
2.3      National and international burdens of CVD and AMI  
CVDs are currently responsible for 30% of deaths worldwide (9).  Every year, 80% 
of the 18 million CVDs deaths occur in low and middle-income countries (9).  In 
developing countries, CVDs primarily affect middle-aged individuals and those older than 
65 years.  Combining years of potential lives lost secondary to premature death and years of 
productive life lost due to disability, the disability-adjusted-life years can reliably estimate 
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the socio-economic impact of CVDs.  CVDs rank second to human immunodeficiency 
diseases, with a loss of 47 million disability-adjusted-life years worldwide on an annual 
basis (11). 
Approximately 82 million American adults (i.e., 1 in 3 Americans) have one or more 
types of CVD (70). In 2007, CVDs were responsible for 8 million hospitalizations in the 
United States, and 450 000 hospitalizations in Canada (71).  Every year, CVD-related 
deaths approximate 785 000 in the United States and 69 000 in Canada (71-72).  
Elimination of CVD would increase life-expectancy by 7 years in the United States, and 3 
years in Canada (71-72). 
Acute and chronic ischemic heart diseases are responsible for most of the CVD 
morbidity and mortality burdens (11).  Ischemic heart diseases are responsible for more 
than 7 million deaths worldwide every year (11).   There were 18 905 Canadian deaths due 
to ischemic heart diseases in 2002 (age and sex-standardized rates of 123/100 000 in males, 
and 64/100 000 in females) (71).  These rates were lower than the American age and sex-
standardized rates of ischemic heart diseases-related mortality, at 145 and 79 per 100 000 
males and females, respectively (71-72).   In 2006, ischemic heart diseases accounted for 
160 323 Canadian hospitalizations (17% of all Canadian hospitalizations) and 13 836 
deaths in Quebec (71-72).  The age and sex-standardized rates of ischemic heart diseases-
related hospitalization were 254/100 000 in Canada and 177/100 000 in Quebec (71-72).  
           AMI occurs when ischemic heart disease leads to partial death of the heart muscle 
(1, 65). Every year, there are 1.3 million AMIs in Europe (73).  In the United States, AMI is 
responsible for 935 000 hospitalizations annually (70). In Quebec, the annual number of 
AMI hospitalizations approximated 15 000 (72).  The age and sex-standardized AMI 
incidence in Canada is summarized in Table 1.  
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Table 1.  Total population, percentage of population ≥65 years old, and incidence of 
acute myocardial infarction-related hospitalizations, by year and province, in Canada 
(71,72). 
 
 
 
Incidence of acute myocardial infarction per  
100 000*  
Year
 
Total population, 
thousands  
(%  ≥65 years old) 
 
2007
 
2008
 
2009
 
Canada 
 
219
 
217
 
209
 
34 108.8 (14)
Newfoundland and 
Labrador 351 347 329 509.7 (15)
Prince Edward Island 308 294 269 142.3 (15)
Nova Scotia 270 264 265 942.5 (16)
New Brunswick 278 269 255 751.8 (16)
Quebec NA 221 214 7 907.4 (15)
Ontario 219 216 207 13 210.7 (14)
Manitoba 253 255 253 1 235.4 (14)
Saskatchewan 227 228 212 1 045.6 (15)
Alberta 221 205 200 3 720.9 (11)
British Columbia 169 169 164 4 531.0 (15)
Yukon 189 199 218 34.5 (8)
Northwest Territories 207 182 250 43.8 (5)
Nunnavut 256 112 192 33.2 (3)
*Adjusted for age, sex and co-morbidity 
2.4 Management of STEMI  
With complete occlusion of the coronary artery, death of the affected heart muscle 
will occur rapidly unless the coronary artery’s blood flow can be promptly restored. It is of 
paramount importance to restore blood flow in the totally occluded coronary artery as 
promptly as possible (1, 76).  Death may occur rapidly due to instability of the electrical 
system of the heart or secondary to acute heart failure. The amount of irreversibly damaged 
heart muscle increases exponentially with increasing time delays to treatment.  Therefore, 
the sooner the coronary artery is opened, the lesser the damage to the heart (1-2,76).  
Restoration of blood flow during the first hour after coronary occlusion (i.e., often referred 
to as the “golden hour”) can completely arrest the progression of the STEMI (1-2,77). 
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Reperfusion therapy (RT) is an intervention to restore blood flow in the affected 
coronary artery. Reperfusion can be accomplished either by administration of an 
intravenous medication (i.e., fibrinolytic therapy (FL)), or by inflation of a special catheter 
in the coronary artery (i.e., primary percutaneous coronary intervention (PCI)) (2).  Delay 
to RT are detrimental because of it increases the risk of permanent heart damage and 
mortality (1-2,76).    
2.4.1 Fibrinolytic therapy  
 Several types of FL medications are available.  There are older medications such as 
streptokinase and urokinase, and newer medications including tissue plasminogen activator 
and tenecteplase.  The newer medications have a success rate of more than 75% in restoring 
the coronary blood flow, compared to approximately 50% success rate with the older 
medications (2).  The cost of FL ranges between 700 $ and 2 700 $ per dose for older type 
and newer type of FL, respectively (77). FL can be injected into a vein by a physician or 
specialized paramedical personnel (i.e., ambulance paramedics or nurses). FL can be 
administered in most emergency rooms or less commonly in the pre-hospital settings (PHL) 
(i.e., at the patient’s home or in the ambulance).     
2.4.2 Primary percutaneous coronary intervention  
Percutaneous coronary intervention (PCI) is a procedure that involves insertion of a 
catheter into the coronary artery to break down the blood clot occluding the coronary flow 
(2).  When the intervention is performed in the context of a STEMI without prior 
administration of FL, it is called “primary PCI” (2).  Primary PCI is highly effective, with 
more than 90% success in restoring the coronary blood flow (2).  The estimated cost of a 
primary PCI is approximately 5 000 $ (77).  
2.4.3 Complications of RT 
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 The main complications of RT include stroke, major bleeding and severe allergic 
reactions (2). Patients with STEMI may experience stroke due to bleeding in the brain or 
dislodging of a blood clot to the brain.  Intracranial bleeding can be life-threatening or 
associated with permanent severe disability.  Intracranial bleeding occurs in 1%-5% of 
patients who receive FL (80).  Stroke is very rare (less than 1%) with primary PCI (81).   
Major bleeding may occur following both types of RT (78). It can be secondary to the 
direct action of FL, or it can be caused by arterial damage related to primary PCI, or it can 
be due to concomitant medications (81).  The cumulative incidence of major bleeding is 
highly variable, ranging from 0%-18%, depending on the definition of major bleeding (81). 
Serious allergic reactions occur in 1% of patients who receive older types of FL such as 
streptokinase and urokinase (2, 81).  Although rare, these reactions are highly lethal.  The 
newer FL agents such as tissue plasminogen activators, reteplase and tenecteplase, are not 
associated with allergic complications (2,81). 
2.4.4 Efficacy and safety of RT 
Summary of results of RCTs of RT 
There are 26 RCTs that compare the efficacy of FL versus primary PCI (12-37). The 
majority of these RCTs have small sample sizes; only six included more than 400 patients 
(12,14-15,21,27,35-36). Since the time interval between publication of the first and last 
RCT on this subject (1993-2008) is long, there is marked heterogeneity across studies in the 
types of FL used as well as adjuvant therapies (81).  There are also marked variations in the 
management of patients with STEMI including in-hospital or pre-hospital administration of 
FL, and primary PCI with or without inter-hospital transfer (81).  The expertise of RT 
providers also varies across studies, with FL administered by less trained EMS personnel 
and primary PCI performed by less expert and experienced physicians in some RCTs (81). 
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Since their statistical powers are limited by their small sample sizes, the primary 
endpoints investigated in several RCTs are most frequently the composite of several 
endpoints.  The most commonly used primary endpoint is a composite of all-cause 
mortality, reinfarction (i.e., recurrence of AMI) and stroke (12-37).  However, these 
separate endpoints have very different clinical impacts, with reinfarction being the most 
benign complication compared to stroke or death (82).  Furthermore, detection and 
ascertainment of reinfarction are highly inconsistent across studies.  All-cause mortality is 
the most objective, reliable and valid endpoint and should have been considered separately 
from the other endpoints (82). 
Potential bias in RCTs 
 Numerous potential biases may have compromised the internal validity of several 
RCTs.  In this section, I summarize these potential biases. The main benefit of 
randomisation is to decrease potential confounding by ensuring equal probability for all 
patients of receiving either therapy, regardless of their characteristics (83).  Prior 
knowledge of the assigned therapy may affect physician and/or patient decision to 
participate in the study.  Therefore, it is crucial that neither the physicians nor the patients 
can predict the RT strategy assigned. Research personnel should not be able to alter the 
randomisation sequence. 
 Randomisation by sealed envelope is subject to manipulation by research 
personnel, if the allocated therapy can be visualized through the envelope (84-86).  
Randomisation remote from the research center should be the most reliable method since 
health care providers cannot tamper with the assignment.  Sealed envelope randomization 
was used in eight (13,16,19-20,23-26) of 25 RCTs, so that randomization in these eight 
studies was subject to manipulation.   
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Randomization may not reduce all important differences in patient characteristics 
between intervention arms.  RCTs with small sample sizes are particularly subject to this 
limitation (83,86-87).   By chance, sicker or older patients may have been assigned to one 
intervention arm compared to the other arm.  We observed a difference of 5 years in mean 
age and ≥10% difference in high-risk features between patients who received FL and 
patients who underwent primary PCI, in several RCTs.  Of the 25 RCTs reviewed, there 
was no notable difference in patient characteristics in only seven studies 
(15,19,21,27,30,33,35-36). 
Due to the natures of the interventions studied, none of the RCTs reviewed could be 
double-blinded.  Therefore, both patients and health care providers were aware of the RT 
assigned, which may have affected the selection of adjuvant therapy.   For example, 
patients randomly assigned to primary PCI would require transfer to tertiary teaching 
hospitals with PCI facility, in contrast to patients who received FL who would stay at 
smaller secondary hospitals.   Patients who underwent primary PCI would be more likely to 
receive more evidence-based concomitant medications and interventions.  The impacts of 
the RT might have been modulated by different concomitant therapies (81).    
 Knowledge of the type of RT received may induce information bias so that both 
care providers and/or patients are more likely to detect and/or report adverse outcomes 
related to the therapy received (81,88).  Patients who received FL and their providers might 
be more likely to detect and report reinfarction and/or stroke symptoms since these 
complications are known to be more frequent with FL than with primary PCI.  This could 
have induced a misclassification bias of the results against FL.  
Misclassification bias might also occur if the endpoint adjudication committee is 
unblinded to the treatment assigned, and adjudicates the endpoints according to their RT 
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preference.   The endpoint adjudicators were blinded to the therapy assigned in only 12 
RCTs (12-15,17,20-23,26,31,37).  Finally, loss to follow-up might induce selection bias 
when the sample of patients followed until the end of the study differs from the sample of 
patients originally enrolled.  In general, follow-up was excellent in most RCTs, with 
complete follow-up in 12 studies (14,16,22-23,25-26,29,31,33,35-37,90). However, in one 
RCT (91) there was notable difference in follow-up between the two treatment arms, 
whereby more high-risk patients were lost to follow-up in the primary PCI arm compared to 
the high-risk patients who received FL (i.e., 58% versus 48%). Therefore, there was a 
potential bias favouring primary PCI in this study, since there might be more adverse 
events in the high-risk patients who were lost to follow-up in this treatment arm.  
External validity of RCTs 
 The applicability of the results of RCTs to the “real-life” context is often assumed 
by the similarity between the patients enrolled and the interventions undertaken in these 
RCTs, with the patients and interventions performed in the “real-life” context.  However, 
the patients enrolled in the RCT are generally younger, have fewer co-morbidity and less 
severe STEMI than “real-life” patients (92-93).  In particular, all RCTs reviewed excluded 
patients at risk of renal failure due to the risk of kidney damage by radiology contrast 
agents (81).  The patients at risk of bleeding were also excluded.  Furthermore, the patients 
with cardiogenic shock (very severe STEMI) were either explicitly excluded or often not 
enrolled due to their inability to provide informed consent (81).   
 Delivery of RT within an “RCT context” is also generally different than delivery of 
RT within the “real-life” context.  The process of obtaining informed consent can be 
lengthy and imposes additional delays to RT administration.  Since the effectiveness of FL 
decreases more with longer time delays compared to primary PCI (76), any consent-related 
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delay might bias against FL. The median time delays to FL exceeded the recommended 
target of less than 30 minutes in several RCTs reviewed (81). On the other hand, primary 
PCI within the RCT context was generally performed expeditiously at excellent large-
volume centers by expert personnel.  The median time delays to primary PCI were 
generally within the target of ≤90 minutes (81).  Timely primary PCI by expert personnel at 
expert centers may not always be possible outside the rigorously controlled conditions of 
RCTs.  Therefore, the superiority of primary PCI over FL might not be able to be entirely 
replicated outside the “RCT” context. 
Meta-analyses of RCT of RT 
         Due to the limited statistical power of most RCTs that compared primary PCI and FL, 
differences in all-cause mortality reduction between primary PCI and FL should be better 
evaluated by using meta-analyses.  I identified 21 published systematic reviews of RCTs 
that compared primary PCI and FL (37, 92-112).  Most meta-analyses showed that primary 
PCI was associated with a 5% mortality reduction compared to streptokinase (i.e., an older 
type of FL) (92).  Primary PCI was associated with a reduction in mortality of 1% 
compared to in-hospital administration of tissue plasminogen activator (i.e., a newer type of 
FL) (92,96-97).  On the other hand, there was no conclusive difference in mortality 
between primary PCI and pre-hospital administration of FL (97).  Furthermore, the 
reduction in mortality of primary PCI was not consistently observed in the meta-analyses 
using more conservative random-effects models (94) and/or Bayesian methodology (100).   
 The majority of the meta-analyses reviewed showed short-term survival benefits of 
primary PCI and reductions in reinfarction and stroke of 1% compared to FL (92-93,95-
96,98-99,101-112).  The superiority in mortality reduction associated with primary PCI 
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compared to FL decreased with longer time delays to primary PCI (110). Primary PCI was 
associated with a 2% increase in major bleeds compared to FL (92).   
 All meta-analyses are potentially limited by publication bias, since authors and 
editors tend not to report research that does not show differences in the outcomes between 
intervention arms (113).  Tests to detect this bias, such as funnel plots and trim and fill 
tests, are poorly sensitive and may not detect omission of major negative studies (110). All 
meta-analyses reviewed are subject to publication bias and might have over-estimated 
treatment effects.   
 The main limitation of several meta-analyses reviewed was the use of fixed- rather 
than random-effects models (37,92,96-98,101,106).  In assuming similarity between the 
trials in terms of patients enrolled and in studies designs, fixed-effects models assume that 
the results are interchangeable across studies (113-114).  Fixed-effects models are often 
employed following negative heterogeneity testing (113-114).  However, the sensitivity of 
heterogeneity testing is poor, and therefore may miss major differences between trials (113-
114).  In these cases, the summary estimates tend to over-estimate the true difference 
between the interventions studied (114). 
 Random-effects meta-analyses assume that all trials are dissimilar and provide more 
conservative summary estimates than fixed-models (113-114).  Summary estimates by 
random-effects meta-analyses are generally closer to the true differences in treatment 
effects than estimates from the fixed models (113-114).  In addition to consideration of the 
differences between trials, Bayesian meta-analysis allows each individual study to borrow 
strength from the summary estimate (115-116).  Hence, Bayesian models allow for better 
designed studies with smaller sample sizes to contribute more to the summary estimate than 
other types of random-effects models (115-116).  Moreover, sub-optimally designed studies 
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with larger sample sizes have less impact on the summary estimate in Bayesian modeling 
(115-116).  Consequently, the estimate of the difference in treatment effects is less likely to 
be biased by sub-optimal large studies in Bayesian meta-analyses (115-116).   
 There were only two meta-analyses that used random-effects Bayesian models.  
However, these meta-analyses were limited by lack of inclusion of recent studies that 
compared primary PCI with newer types of FL (100,110).  Consequently, a new Bayesian 
meta-analysis including more recent RCTs is indicated, and is the rationale for the first 
manuscript of this doctoral dissertation (66).  
Summary of results of observational studies 
          There are 31 observational studies that compared primary PCI and FL (3-4,117-145). 
The majority of studies showed that primary PCI was superior to in-hospital FL 
administration in reducing short and long-term mortality (117,119-120,124-126,129-
130,134-136), in-hospital stroke (3,80,126-128,132,135-136,138-139) and reinfarction 
(120,126,136).  However, the survival advantage of primary PCI was not consistently 
present in the four studies that compared primary PCI to pre-hospital administration of 
fibrinolytic therapy (PHL) (4,120,144-145).  Primary PCI reduced mortality compared to 
PHL in one study (120), while a survival advantage with PHL was observed in another 
study (120), and no survival difference was observed between the two treatment arms in 
two other studies (144-145).  
Potential biases of observational studies 
Observational studies are often considered to be of inferior quality compared to 
RCTs, since they are more susceptible to bias and in particular to selection and 
confounding bias (39,146-149).  Because treatment assignment is not controlled, there are 
frequently imbalances in the characteristics of patients enrolled that may bias treatments 
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effects (146-151).  In the observational studies reviewed, a specific type of confounding 
bias, “confounding by indication” is of particular concern (151).  This bias occurs when 
patients with cardiogenic shock (i.e., very severe STEMI) undergo primary PCI since it is 
the recommended RT in these patients (78).   Inclusion of these patients in may bias against 
primary PCI since this might increase the mortality rate of primary PCI compared to FL.  
Selection bias might impact observational studies in several ways (146-149). To 
avoid selection bias, all analyses should be performed using an intention-to-treat approach.  
Since primary PCI requires much longer time delays than FL, patients assigned to primary 
PCI might die while awaiting this intervention.  Since administration of FL requires shorter 
time delays, patients receiving this treatment would be less likely to die before receiving 
FL.  Exclusion of patients who die before receiving RT from the analyses, would induce 
selection bias in favour of primary PCI. Selection bias may also occur with sub-optimal 
follow-up when there was no consideration of events in patients lost to follow-up (146-
149).  Moreover, since observational studies might not have rigorously pre-defined their 
methodology for event detection and classification, these studies may also be subject to 
detection and misclassification bias (146-149).   
Strengths of observational studies 
Despite potential biases, well-designed observational studies may produce results as 
relevant as those of RCTs (39,150). High-quality cohort studies should involve concurrent 
rather than historical controls, clearly described inclusion criteria, definition of zero-time 
(i.e., time of study start) and adequate adjustment for differences in characteristics of 
patients between intervention arms (39,150).   Furthermore, observational studies may 
address the limited external validity of many RCTs.   Observational studies can provide 
unique “real-life” perspectives by including older and sicker patients who are frequently 
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excluded from RCTs (39).  Effectiveness and safety of primary PCI undertaken in less than 
ideal conditions (i.e., low volume and less expert centers, lengthy time delays to RT) are 
best evaluated in observational studies (39,150).  Observational studies with long follow-up 
periods are also more suitable than RCTs to assess the safety profile of RT in less selected 
patients with STEMI (39,150). 
Rationale for a meta-analysis of observational studies 
         A systematic review of observational studies on RT has never been published.  A 
Bayesian meta-analysis of observational studies may provide a better understanding of 
several aspects of RT that cannot be adequately evaluated in RCTs, including effectiveness 
and safety of RT in less selected patients with STEMI.  This was the rationale for the 
Bayesian meta-analysis of observational studies in the first manuscript of this dissertation.  
(Manuscript 1).  
2.4.5 Pre-hospital management of patients with STEMI 
 Although much less attention has been directed to pre-hospital emergency medical 
services (EMS) than to in-hospital management of a patient with STEMI, early EMS 
intervention can abort a STEMI and can improve patient outcomes (151-153).  Prior to the 
introduction of primary PCI and PHL, traditional EMS management of  patients with 
STEMI involved prompt transportation of these patients to the closest hospital only, 
regardless of whether or not this hospital had a PCI facility (154).  During the past decade, 
several EMS innovations may have reduced time delays to RT such as 1) EMS diagnosis of 
STEMI (78,154-155), 2) EMS alert of ER personnel of the impending arrival of patients 
with STEMI (78-79,154-158) and 3) EMS administration of FL (PHL) (78-79, 151-
153,157-158).  
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 Diagnosis of STEMI is a two-step process: 1) electrocardiogram (ECG) acquisition 
and 2) ECG interpretation (1) (154).  Although ECG acquisition skills can be learned 
rapidly, ECG interpretation is more complex. A false negative diagnosis of STEMI may 
delay RT, while a false positive diagnosis of STEMI may lead to inappropriately 
administered RT and may expose the patient to unnecessary life-threatening complications 
of RT (154). 
 EMS interpretation of ECG can be automated (i.e., generated electronically by a 
computer) or undertaken by EMS personnel or by a physician (154).  Since most EMS 
systems do not have physician in the ambulances, interpretation of pre-hospital ECGs by a 
physician is only possible with transmission of these ECGs (154).  However, ECG 
transmission may not be feasible due to lack of a wireless telephone system or lack of a 
physician assigned to this task (154).  In these cases, automated and/or a paramedic’s 
interpretation of the ECG may be used despite lower accuracy in ECG interpretation 
compared to physician’s ECG interpretation (154).   
 EMS alert of ER personnel of the impending arrival of patients with STEMI can 
reduce time delays to RT (158).  ER personnel can notify PCI personnel and/or prepare FL 
during the transportation of patient to the hospital. However, although alert of ER personnel 
by EMS appears to be straightforward, this step requires accurate EMS diagnosis of STEMI 
(154).  Unnecessary and/or inappropriate notification of PCI personnel is costly and can 
divert ER care from other patients (154).    
 Compared to in-hospital administration of FL, PHL reduce times delays to FL (152-
153), and therefore can improve survival of patients with STEMI (40).  In rural areas, PHL 
may be the only RT strategy that can be available in a timely manner (79, 157). Despite the 
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complexity of PHL, the European Society of Cardiology has endorsed and implemented 
PHL, for over two decades, in Europe (152).   
Care of patients with STEMI may be coordinated within a local network of EMS 
personnel and hospitals with or without a PCI facility (i.e., regionalized STEMI care) 
(79,155-157).   Although the infrastructure and organization of STEMI care differs 
considerably between regions, regionalized STEMI care most frequently involves direct 
transportation of patients with STEMI by EMS to a hospital with PCI facility (PCI-
hospital) rather than to the hospital closest to the patient (79,155-159).  However, it remains 
unclear whether EMS transportation of patients with STEMI directly to a PCI-hospital is 
superior in reduction of mortality compared to transportation to the closest hospital.  A 
meta-analysis of RCTs and observational studies reported an inconclusive difference in 
mortality between direct transportation of patients with STEMI to a PCI-hospital compared 
to transportation of these patients to the closest hospital (160). 
 Finally, it is essential to recognize the complexity of EMS organization.  Pre-
hospital STEMI care requires major investment that may divert resources from other 
critical areas.  Large numbers of primary PCI-related ambulance transfers (i.e., direct 
transportation of patients with STEMI to a PCI-hospital bypassing the closest hospital, 
inter-hospital transfer for primary PCI, inter-hospital transfer back to the referring hospital) 
would reduce the number of ambulances available for other types of EMS care. Availability 
of ambulances is particularly critical in rural areas, where an ambulance cannot be occupied 
for prolonged periods to care for a single patient with STEMI.  The quest for optimal pre-
hospital STEMI management should be carefully planned to avoid jeopardizing STEMI 
patients by inappropriately delaying RT and depriving patients with other diseases of 
optimal EMS care. 
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2.4.6 Overview of national infrastructure and processes of care of patients with STEMI  
In this section, we describe national and provincial pre- and in-hospital infrastructure 
currently available for managing patients with STEMI.   
 Pre-hospital care for patients with STEMI in Canada 
 EMS technicians (i.e., paramedics) are trained at different levels of expertise: 
advanced, intermediate and basic care (161). Paramedics trained in advanced care can 
manage patients without a physician’s assistance.  They can independently administer 
almost all medications, identify and manage patients with STEMI without requiring 
assistance by a physician (161).  Paramedics trained in intermediate care can administer a 
limited number of medications and acquire ECG (161). They require assistance from a 
physician (generally by telephone) to manage patients with STEMI (161).  Paramedics 
trained in basic care can only transport patients and perform basic cardiac resuscitation 
(161).  
 In manuscript 2 of this thesis, I describe variations in the infrastructure and processes 
of care as well as in the expertise of EMS personnel across several international settings. 
European EMS systems of care have the most expert personnel in the ambulances (i.e., 
physicians in France and Vienna, nurses in Sweden, paramedics trained in advanced cardiac 
care in the United Kingdom) (6,67).   At the present time, most Canadian EMS systems 
have paramedics trained in advanced care, except in Quebec where most paramedics are 
only trained in intermediate care (161-162).   
I summarize the key processes of EMS management of patients with STEMI in five 
Canadian provinces (85% of Canadian population) in Table 2.   Less than half of Canadian 
paramedics can interpret ECG, and only a minority can transmit the pre-hospital ECG 
(162).  Despite being the most populated provinces with the highest proportions of elderly, 
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EMS systems in Ontario and Quebec are the least developed, with fewer paramedics trained 
in ECG interpretation and transmission, PHL and re-direction of patients to PCI-hospitals 
(162).  Alberta has the most organized EMS system of STEMI care, with the highest 
proportion of paramedics trained in PHL and in ECG acquisition, interpretation and 
transmission (162).   
 Overall, numerous obstacles limit optimal EMS management of patients with STEMI 
in Canada compared to European countries.  In contrast to Europe, where PHL is 
successfully implemented in many countries (6,67,73), PHL is currently available in only 
two Canadian provinces (Alberta and Nova Scotia) (67).  Considering its vast territory and 
its large rural population, Canada can potentially derive considerable benefit from more 
widespread implementation of PHL (67).  
Table 2.  Expertise of paramedics in STEMI care in selected Canadian provinces, 
(162-163).  
 
 Province  
(year with available data) 
 
 
Expertise 
Canada 
(2007)
Quebec 
(2011)
Ontario 
(2007)
Alberta 
(2007) 
British 
Columbia 
(2007)
Nova 
Scotia 
(2007)
ECG acquisition, % of 
paramedics 47 100 55 80 10 80
ECG interpretation, % of 
paramedics 40 35 50 70 10 70
ECG transmission, % of 
paramedics 20 20 5 70 10 70
Expedited inter-hospital 
transfer to PCI-hospital, % of 
paramedics 45 NA 45 50 100 NA
Pre-hospital re-direct of 
patients with STEMI to PCI-
hospital, % of paramedics 18
In urban 
areas only 10 50 100 NA
Pre-hospital fibrinolysis, % of 
paramedics 8 0 0 50 0 
Pilot 
project
ECG:  Electrocardiogram 
NA:  Not Available 
PCI:   Percutaneous Coronary Intervention  
STEMI:  ST-Segment Elevation Myocardial Infarction 
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Pre-hospital care of STEMI in Quebec 
 In Quebec, physicians are rarely present in ambulances (161).  Management of 
patients in ambulances is generally under the responsibility of paramedics (161) with 
medical assistance available by phone only (161).  In contrast to all other Canadian EMS, 
Quebec paramedics are only trained in intermediate care (161) and therefore can only 
perform basic management of STEMI patients (161).  They cannot administer any drug 
intravenously (161).   
 Consequently, EMS STEMI management in Quebec has been limited to on-scene 
stabilization and transportation of patients to the assigned hospital (161).  Compared to 
other jurisdictions, EMS interventions in Quebec are markedly limited in scope.  For 
example, pre-hospital ECG is available in Quebec only since 2009 (164) compared to 
availability of this technique since 1990 in Sweden (67).  The main obstacle to optimal 
EMS management of patients with STEMI in Quebec includes provision of care to a 
relatively small population distributed across a very large territory (165).  Access to and 
transportation of patients in rural areas can be lengthy and problematic in Quebec, 
especially during the winter months (165)  
 In recent years, primary PCI has emerged as the preferred RT in Quebec (166).  
Quebec EMS redirects patients with STEMI more frequently to a PCI-hospital than to the 
closest hospital (166).  Although re-direction of patients to a PCI-hospital (rather to the 
closest hospital) has been shown to be safe in Europe (27,28), ambulance transportation in 
Europe is generally within short distances and with expert medical escorts (i.e., physicians, 
intensive care nurses and/or advanced care paramedics) (66).   The safety of transporting 
patients with STEMI by intermediate care paramedics to a PCI-hospital rather than to the 
closest hospital remains to be determined in Quebec.   
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Overview of structures of in-hospital STEMI care in Canada 
         The infrastructure for in-hospital STEMI care in Canada overall and five Canadian 
provinces are described in Table 3 (167).  There are 1 449 PCI hospitals in the United 
States, with a ratio of one PCI-hospital per 215 359 Americans (168). In contrast, there are 
40 Canadian PCI-hospitals, with a ratio of 1 PCI-hospital per 852 725 Canadians (169).  
Compared to other provinces, Quebec has the most PCI-hospitals per population (1 per 608 
230) compared to 1 PCI-hospital per 943 571 in Ontario population, 1 per 1 240 333 in 
Alberta, 1 per 1 132 750 in British Columbia, and 1 per 942 500 in Nova Scotia (163,169).    
Due to the smaller number of PCI-hospitals and more sparsely distributed population, 
only 64% of Canadians live within 60 minutes of a PCI-hospital, compared to 79% of 
Americans (168,169).  Compared to other provinces, Ontario has the most optimal 
geographic distribution of PCI-hospitals.   Seventy-three percents of the Ontario population 
live within a 60-minute access to a PCI-hospital compared to 69% of the Quebec 
population, 63% of Albertans, and 58% of British Columbians (169).  
Table 3. In-hospital infrastructure for STEMI care in the United States and Canada 
(163,167-169)  
 Canada Quebec Ontario Alberta British 
Columbia 
Nova 
Scotia 
Number of ER 
capable of RT 
NA 111 NA NA NA 943 
Number  of PCI-
hospitals 
40 13 14 3 4 NA 
Population per 
PCI-hospital 
852 725 608 230 943 571 1 240 333 1 132 750 942 500 
% of population 
≤30 minutes of a 
24/7 ER 
NA 94.0 NA NA NA NA 
% of population ≤ 
60 minutes of a 
PCI-hospital 
64 69 73 63 58 36 
 
% of population ≤ 
120 minutes of a 
PCI-hospital 
 
 
79 
 
 
87 
 
 
92 
 
 
72 
 
 
64 
 
55 
25 
 
25 
 
% of population ≤ 
90 minutes of a 
PCI-hospital 
72 80 83 68 63 42 
 ER: Emergency room 
NA Not available 
PCI-hospital: Hospital with facility for percutaneous coronary intervention 
24/7:  opened 24 hours on 7 days  
 
2.5. Outcomes of patients with AMI  
2.5.1 Mortality of patients with AMI 
The 30-day mortality rates adjusted for age, sex and co-morbidity in some Canadian 
provinces are reported in Table 4 (171-172). Risk-standardized 30-day mortality is not 
available for Quebec due to co-morbidity coding different from other provinces (171-172).  
There is a 25% absolute decrease in AMI-related mortality in less than a decade (1998-
2006) (171-172).  This decline in AMI fatality in Canada is remarkable considering that the 
declines in fatality for two other important CVDs such as congestive heart failure and 
stroke, remain unchanged in Canada during the same decade (171-172).  
Table 4.  Thirty-day AMI-related mortality*, in Canada, (1998-2006) (171-172). 
 Year 
 1998 1999 2000 2001 2002 2003  2004  2005 2006 
Canada 
12.6
 
12.1 
 
11.8
 
11.4
 
11.3
 
11.1 
 
10.3  
  
10.0
  
9.4 
 
Newfoundland and Labrador NA 13.5 12.1 
Prince Edward Island 12.7 12.3 12.0 13.0 14.6 14.3 14.2 12.8 11.3
Ontario 12.8 12.4 12.0 11.3 11.2 11.1 10.2 9.9 9.4
Manitoba 12.1 11.5 11.5 12.2 12.0 11.4 9.6 9.2 8.6
Saskatchewan 14.6 12.5 11.9 11.8 11.6 10.9 10.1 9.6 9.5
Alberta 10.4 9.9 9.6 10.2 9.4 9.3 8.2 8.4 7.8
*=AMI-related mortality adjusted for age, sex and co-morbidity  
AMI: Acute Myocardial Infarction 
NA:  Not available  
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2.5.2 Re-hospitalization of patients with AMI 
The 30-day AMI-related re-hospitalization can be a measure of the quality of care 
provided to patients with AMI since most of these patients should not require a re-
hospitalization within 30 days (172).  This outcome may reflect inadequate care, 
insufficient discharge planning and/or sub-optimal follow-up.  Re-hospitalization rate 
should be adjusted for age and co-morbidity, since older patients with more co-morbidity 
are more likely to be re-hospitalized. The 30-day AMI-related re-hospitalization rates 
adjusted for co-morbidity, age and sex are summarized in Table 5.   
The national 30-day rehospitalisation approximated 5% with the lowest rates 
observed in Alberta. There is a 35% decrease in 30-day re-hospitalization in Canada since 
1998 (171-172).  It is not possible to compare the 30-day AMI-related re-hospitalization 
rate in Quebec with other provinces due to different co-morbidity coding (171).   
Table 5. Thirty-day AMI-related re-hospitalization adjusted for age, sex and co-
morbidity in Canada, (1998-2006) (171-172).  
Year 1998 1999 2000 2001 2002 2003  2004  2005 2006 
Canada 7.3 
 
6.7 
 
4.5 
 
6.9 
 
7.1 
 
6.2  
 
5.6 
 
5.1 
 
4.7 
 
Newfoundland and Labrador NA 7.5 7.1 6.2 5.9
Prince Edward Island 10.7
 
10.8 6.5 8.3 
 
11.4 9.6 8.5 6.4 
 
5.9
Nova Scotia 8.6 
 
8.6 5.1 
 
9.0 
 
8.7 7.8 7.0 6.2 5.5
New Brunswick 8.6 
 
8.6 5.1 
 
9.0 
 
8.7 7.8 7.0 6.2 5.5
Quebec 6.3* NA 
Ontario 7.5 
 
6.9 
 
4.7 
 
7.2 
 
7.2 
 
6.1 
 
5.4 
 
4.9 
 
4.6 
 
Manitoba NA 5.8 
 
5.2 
 
5.1 
 
Saskatchewan 6.2 5.9 4.2 7.2 7.3 7.0 6.6 5.9 5.0 
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Alberta 5.6 
 
5.3 3.5 4.9 4.8 4.4 4.2 4.0 3.7
British Columbia 7.3 
 
6.6 
 
4.0 6.4 
 
7.4 
 
6.2 
 
5.6 
 
5.3 
 
NA
AMI: Acute Myocardial Infarction   
NA:  Not available  
*:  Age and sex-adjusted only 
 
2.6 Outcomes of patients with STEMI 
 
2.6.1 In-hospital mortality of patients with STEMI in several international registries 
 
There is a remarkable international variation in the short-term mortality of patients 
with STEMI (Table 6).  The rates varied from 4% in rural Illinois (176) to 10% (North 
Carolina) (179).  It is not possible to compare these rates directly due to the inability to 
adjust for age and co-morbidity.  There was no notable secular trend with the highest 
mortality (10%) reported for a fairly recent large cohort of patients with STEMI in North 
Carolina (RACE) (179).  Mortality rate was 8.0% in the United States during 2003-2005 
(139), and 8.5% in the United Kingdoms during 2009-2010 (151).  
Table 6.  Short-term mortality of patients with STEMI in several countries (during 
1999-2010) (120,127-128,134, 139, 146,173-175,176-181). 
 
   Names of studies (country) 
 
 
 
Year 
 
N of patients 
(Mortality* stratified 
by RT, %) 
Register of Information and Knowledge about 
Swedish Heart Intensive Care Admissions 
(RIKS-HIA), (Sweden) (120) 
1999-2004 16 043 FL (8.8) 
7 084 primary PCI 
(3.5)
Global Registry of Acute Coronary Events 
(GRACE), (Global) (128) 
1999-2000 3 419** (7.0)
Dryja et al., (Poland) (134) 2003 240 FL (7.9) 
422 primary PCI (5.5)
Vienna STEMI registry, (Austria) (127) 2003 281 FL (8.2) 
631 primary PCI (8.1)
EURO-HEART Survey of Acute Coronary 
Syndromes, (Europe) (174) 
2000 4 431** (7.0)
EURO-HEART Survey of Acute Coronary 
Syndromes, (Europe) (175) 
2004 3 004** (7.2)
COsti  benefici delle strategie di 
RIperfusione nell’infarto miocardico acuto con ST 
sopralivellato, (Italy) (173) 
2002-2004 812 (23.9)*** 
902 (19.8)*** 
Global Registry of Acute Coronary Events  2005 992** (4.6)
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(GRACE), (Global) (128) 
National Registry of Myocardial Infarction (NRMI-
3/4) (United States) (139)  
2003-2006 118 218** (8.0) 
 
Minneapolis, (United States)  (177) 2003-2006 
 
NA for FL 
1 345 primary PCI 
(4.9)
Mayo Clinic, (United States)  (178) 
 
2004-2006 131 FL (3.1) 
258 Primary PCI 
without inter-hospital 
transfer: (6.6) 
105 Primary PCI with 
inter-hospital  transfer:  
(5.7)
French Registry on Acute ST-Elevation Myocardial 
Infarction (FAST-MI),  (France) (146) 
2005 466 FL  (4.3) 
564 primary PCI (5.0) 
Reperfusion in Acute Myocardial Infarction in 
Carolina (RACE), (United States) (179) 
2007 6 565** (10.1)
StatHeart Program, (United States)  (176) 2005-2007 188** (3.7)
Croatian Primary PCI Network, (Croatia) (180) 2008 1 190** (4.4)
Myocardial Ischemia National Audit Program  
(MINAP), (England and Wales) (181) 
2009-2010 31 430** (8.5)
FL:  Fibrinolytic Therapy 
NA :  Not Available 
PCI:  Percutaneous Coronary Intervention 
RT:  Reperfusion Therapy  
*:  30-day mortality or in-hospital mortality if 30-day mortality was not available 
**:  Type of reperfusion therapy was not specified 
***:  Includes patients who did not receive reperfusion therapy 
 
2.6.2 In-hospital mortality of patients with STEMI in several Canadian registries 
 
Data on in-hospital mortality of patients with STEMI in Canada are reported in Table 7.  
The in-hospital mortality varies markedly with rates ranging from 1.5% to 10.9%.  In-
hospital mortality approximates 6% in two large cohorts (168,182). 
Table 7.  Short-term mortality of patients with STEMI in Canada. 
 
Registry 
 
Year 
 
Regions 
 
 Patients who 
received FL 
N (mortality*, 
%)
 
Patients who 
underwent primary 
PCI 
N (mortality*, %)
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AMI-QUEBEC (182) 2003 Quebec 476 (5.6) 604 (7.9)
Matteau et al. (183) 2004-5 Montreal NA 129.(10.9)
De Villiers et al. (160) 2005-6 Calgary NA 358 (3.1)
Lemay et al. (119) 2005-6 Ottawa NA 344 (4.7)
Quebec Heart and Lung 
Institute (184) 
2004-5 Quebec city NA 197 (1.5)
Lambert et al. (168) 2006-7 Quebec 392 (6.1) 1 440 (5.6) 
 
Danault et al. (185) 
 
2008 Sherbrooke NA 370 (3.2)
GRACE, GRACE2, 
CANRACE (186) 
1999-
2008
Canada 1 308 (3.7) 716 (2.7)
AMI-QUEBEC:  Acute Myocardial Infarction in Quebec  
FL:  Fibrinolytic Therapy  
CANRACE: Canadian Registry of Acute Coronary Events  
GRACE:  the Global Registry of Acute Coronary Events GRACE2: Expanded GRACE  
NA:  Not available 
PCI:  Percutaneous Coronary Intervention 
*:  30-day mortality or in-hospital mortality if 30-day mortality was not available 
 
2.7 Management of patients with NSTE-ACS 
        Since the culprit coronary artery in patient with NSTE-ACS is only partially occluded, 
damage to the heart muscle of these patients is generally less extensive and the risks of 
mortality and heart failure are lower than those of patients with STEMI (187).  The impact 
of delays to treatment on outcome of patients with NSTE-ACS is not as crucial as in 
patients with STEMI (187).  Management of patients with NSTE-ACS frequently involves 
medications to thin the blood in the coronary artery (anti-platelets, blood thinners), 
medications to decrease the workload of the heart (anti-anginals), and non-urgent PCI 
(187).   
2.7.1 Importance of risk stratification of patients with ACS   
Patients with ACS have a very wide range of mortality risks that range from less 
than 5% to more than 80% (187-189).  High-risk patients with ACS may derive survival 
benefit with potent medications and prompt coronary intervention (187-189).  On the other 
hand, inappropriate use of aggressive medical and invasive interventions in low-risk 
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patients with ACS may only expose these patients to unwarranted adverse effects without 
benefit (187-189).     
Rapid EMS risk stratification of patients with ACS may convey substantial benefit 
(158).  Since early PCI is the treatment of choice for high-risk ACS, prompt identification 
of these patients is critical (158,164).  Routine transfer of all ACS patients to PCI-hospitals 
would require large investments in EMS resources without benefitting the majority of these 
patients (192).  Therefore, early pre-hospital risk stratification would benefit considerably 
patients with ACS in terms of directing them to the most appropriate hospitals (158).  
Despite their abundance, risk scores are rarely applied in the management of 
patients with ACS (190).  Health care providers often find data extraction and computation 
of risk scores inconvenient (190).  There are frequent misperceptions that physician 
assessment alone is adequate for risk stratification of ACS patients (190).    However, 
physician risk assessment is inferior to formal risk scores in predicting the risk of adverse 
events in patients with ACS (191). 
I identify and summarize the characteristics and limitations of 25 ACS risk scores in 
Table 8. Most risk scores can only be applied in-hospital, once laboratory results become 
available.  Eight of these risk scores can be applied at the time of the first EMS contact with 
the patients.  Nevertherless, a few limitations hinder the use of these scores in early risk 
stratification, such as requirement for an ECG in three scores, requirement of a calculator or 
hand-held computer in four scores, and applicability in only selected patients in two scores.  
Of all published risk scores, none has all desired attributes for early risk 
stratification of patients with ACS.  In the third manuscript of this doctoral dissertation, I 
develop and validate a simple and accurate risk score that may be used for early risk 
stratification of patients with ACS. 
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Table 8.  Characteristics of available scores for risk stratification of patients with 
acute coronary syndromes  
 
Risk scores 
(alphabetical 
order) 
Target 
populations 
Indicators 
required 
Tools 
required for 
computation
Time of 
application 
Predicted 
survival 
Limitations
AMIS (41) All types 
of ACS 
Age, Killip 
class, BP, 
pre-hospital 
cardiac arrest, 
history of 
heart failure, 
and cerebro-
vascular 
disease
Hand-held 
computer 
Can be 
applied at 
time of the 
first 
contact 
with the 
patient 
1-year • Requires 
history 
taking 
• Requires 
training 
for Killlip 
class 
APEX AMI 
(42) 
Patients 
with 
STEMI 
who 
undergo 
primary 
PCI 
Age, BP, HR, 
laboratory 
values and 
ECG 
Nomogram Can be 
applied 
only after 
laboratory 
values 
become 
available
90-day • Required 
laboratory 
results 
• Requires 
ECG  
CADILLAC 
(43) 
Patients 
with 
STEMI 
who 
undergo 
primary 
PCI 
Age, 
laboratory 
values, Killip, 
angiogram 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
coronary 
angiogram 
results 
become 
available
1-year • Requires 
coronary 
angiogram 
• Requires 
training 
for Killip 
CCP (44) All types 
of ACS 
Age, cardiac 
arrest and 
heart failure, 
BP, HR, ECG 
findings and 
laboratory 
values 
Hand-held 
computer 
Can be 
applied 
only at 
discharge 
30-day • Mainly 
used as 
risk 
adjustment 
between 
hospitals 
• Validated 
in patients  
≥65 years 
old only
EMMACE 
(45) 
All types 
of ACS 
Age, BP and 
HR 
Calculator Can be 
applied at 
time of the 
first 
contact 
with the 
patient
30-day • Requires 
calculator 
 
FRISC-II 
(46) 
NSTEMI Age, male, 
diabetes, 
ECG and 
laboratory 
values 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
laboratory 
results 
1-year • Delay 
required 
for 
laboratory 
results
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become 
available
GRACE 
(47-48) 
All types 
of ACS 
Age, BP, HR 
history of 
heart failure, 
ECG and 
laboratory 
results 
Hand-held 
computer 
Can be 
applied 
only after 
laboratory 
values 
become 
available
6-month • Requires 
history 
taking 
• Requires 
calculator 
 
GUSTO 
(49) 
STEMI Age, HR, BP, 
Killip history 
of 
hypertension, 
cerebro-
vascular 
disease, 
rrhythmia and 
ECG 
Can be 
calculated 
by hand 
Can be 
applied 
only at 
hospital 
admission 
30-day • Requires 
history 
taking 
• Requires 
training 
for Killlip 
class 
• Requires 
ECG  
• Can be 
applied 
only at 
hospital 
admission
KAMIR 
(50) 
NSTEMI TIMI risk 
index, Killip, 
ECG and 
laboratory 
values 
Calculator Can only 
be 
obtained 
in ER after 
laboratory 
results 
become 
available
1-year • Delay 
required 
for 
laboratory 
results 
Lloyd-Jones 
et al. (51) 
NSTEMI Age, prior 
MI, diabetes 
mellitus, 
heart failure, 
ECG , 
medication 
use, and 
laboratory 
values
Can be 
calculated 
by hand 
Can be 
applied 
only at 
discharge 
10-year • Can only 
be used at 
hospital 
discharge 
Mayo Risk 
score (52) 
All types 
of ACS 
Age, female 
sex, BP, 
Killip, 
laboratory 
values and 
ECG 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
laboratory 
results 
become 
available 
30-day • Delay 
required 
for  
laboratory 
results 
• Requires 
training 
for Killip 
class 
PAMI (53) STEMI Age, HR 
Killip and 
ECG 
Can be 
calculated 
by hand 
Time of 
first 
contact 
6-month • Can only 
be used in 
patients 
33 
 
33 
 
with the 
patient 
either pre-
hospital or 
in the ER 
with 
STEMI 
• Requires 
training 
for Killip 
class  
• Requires 
ECG 
PEPA (54) NSTE-
ACS 
Age, diabetes, 
Killip, ECG 
and 
laboratory 
values 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
laboratory 
results 
become 
available 
90-day • Delay 
required 
laboratory 
results 
• Requires 
training 
for Killip 
class  
Piombo et 
al. 
(55) 
Unstable 
angina 
Age, prior 
coronary 
artery bypass 
surgery, ECG 
and 
laboratory 
results
Can be 
calculated 
by hand 
Can be 
applied 
only after 
laboratory 
results 
become 
available
In-
hospital 
• Requires 
ECG and 
laboratory 
results 
PREDICT 
(56) 
All types 
of ACS 
Age, BP, HR, 
history of 
diabetes, 
stroke, 
myocardial 
infarction, 
CABG 
hypertension, 
ECG and 
laboratory 
values
Normogram Can be 
applied 
only after 
laboratory 
results 
become 
available 
6-year • Requires 
ECG and 
laboratory 
results  
PRISM-
PLUS (57) 
NSTE-
ACS 
Age, prior 
CABG, prior 
medication 
use and ECG 
Can be 
calculated 
by hand 
Can be 
applied at 
the time of 
first 
contact 
with 
patient
7-day • Requires 
ECG and 
laboratory 
results 
PURSUIT 
(58) 
NSTEMI Age, sex, BP, 
HR, presence 
of heart 
failure and 
ECG 
Can be 
calculated 
by hand 
Can be 
applied at 
the time of 
first 
contact 
with 
patient 
30-day • Requires 
training to 
recognize 
heart 
failure 
• Requires 
ECG 
RUSH (59) Patients 
with 
unstable 
angina 
Age, history 
of myocardial 
infarction or 
diabetes, 
Calculator Can be 
applied 
only at 
hospital 
In-
hospital 
• Requires 
history 
taking 
• Can be 
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medications 
use 
admission applied 
only at 
hospital 
admission
Shock index 
(60) 
Patients 
with 
STEMI 
who 
underwent 
PCI 
BP and HR Can be 
calculated 
by hand 
Can be 
applied at 
the time of 
first 
contact 
with the 
patient
In-
hospital 
• No 
external 
validation 
available  
TIMI-II (61) STEMI Age, sex, BP, 
diabetes 
mellitus, 
heart failure,  
and ECG 
Can be 
calculated 
by hand 
Can be 
applied at 
the time of 
first 
contact 
with the 
patient 
6-week • Requires 
ECG  
• Requires 
training to 
recognize 
heart 
failure 
TIMI score 
(62) 
Different 
risk models 
for STEMI 
and 
NSTEMI 
History, ECG 
and 
laboratory 
results (for 
STEMI:  
weight is also 
required) 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
laboratory 
results 
available 
1-year • Difficult 
to 
memorize 
• Requires 
ECG and 
laboratory 
results 
• Requires 
weight for 
patients 
with 
STEMI 
(not 
available  
generally 
in the pre-
hospital 
setting) 
 
TIMI Index 
(63) 
All types 
of ACS 
Age, BP and 
HR 
Calculator Can be 
applied at 
the time of 
first 
contact 
with the 
patient
10-year • Requires 
calculator 
ZWOLLE 
(64) 
STEMI Age, Killip, 
ECG  and 
coronary 
angiogram 
Can be 
calculated 
by hand 
Can be 
applied 
only after 
coronary 
angiogram 
obtained 
30-day • Requires 
training 
for Killip 
class  
• Can only 
be used in 
patients 
with 
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STEMI 
and only 
after 
coronary 
angiogram 
completed  
 
AMI:  Acute Myocardial Infarction 
AMIS:  Acute Myocardial infarction in Switzerland 
APEX AMI:  Assessment of Pexelizumab in Acute Myocardial Infarction Trial 
CABG:  Coronary Artery Bypass Surgery 
CADILLAC:  Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications 
CCP:  Cooperative Cardiovascular Project 
EMMACE:  Evaluation of Methods and Management of Acute Coronary Events 
FRISC-II:  Fast Revascularisation in Instability in Coronary Disease 
GRACE:  Global Registry of Acute Coronary Events 
GUSTO:  Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries 
KAMIR:  Korea Acute Myocardial Infarction Registry 
NSTEMI:  Myocardial Infarction without ST-Segment Elevation 
PAMI:  Primary Angioplasty in Myocardial Infarction 
PEPA :  Proyecto de Estudio del Pronóstico de la Angina 
PURSUIT :  Platelet glycoprotein Iib/IIIa in Unstable angina: Receptor Suppression Using Integrilin 
(eptifibatide) Therapy 
PREDICT:  Predicting Risk of Death in Cardiac Disease Tool 
PRISM-PLUS: Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by 
Unstable Signs and Symptoms trial 
RUSH:  Rush-Presbyterian-St. Luke’s Medical Center Study 
STEMI:  Myocardial Infarction with ST-Segment Elevation 
TIMI:  Thrombolysis in Myocardial Infarction 
 
 
2. 8. Conclusion of the literature review 
 In summary, CVDs remain leading causes of mortality world-wide (9-10).  AMIs 
are responsible for most of the CVDs burdens (9-10).  In view of the aging population and 
increasing prevalence of diabetes mellitus and obesity (9-10), the global societal impact of 
AMI will become enormous.   One type of AMI, STEMI, is highly lethal and should be 
diagnosed and treated promptly (1).  There are marked variations internationally and 
nationally in the infrastructure for the management of patients with STEMI.  The current 
EMS management of patients with STEMI in Quebec has many deficiencies (161-164).   
There is a remarkable 25% decline in AMI case fatality in Canada during the last 
two decades.  The Canadian in-hospital AMI mortality of 9% (172) is similar to the 
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mortality rates of AMI in many countries (139,174-181).  Short-term STEMI-related 
mortality of 6% in Quebec (168, 182, 185) appears to be similar to the STEMI-related 
mortality in other jurisdictions.   
Remarkable progress has been made in reducing mortality of patients with ACS in 
Canada and in other developed countries.  Nevertherless, there remain major opportunities 
to improve ACS care, including more widespread pre-hospital implementation of ECG, 
PHL, and early EMS risk stratification (164). Since ACS constitute the bulk of CVDs (4), 
interventions to reduce mortality and morbidity of patients with ACS would substantially 
reduce the CVDs burdens.    
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Chapter 3. 
 
Rationale and objectives of the thesis 
The literature review identified three key gaps in the current scientific knowledge:   
1.      There remains uncertainty in terms of whether the superiority in mortality reduction 
with primary percutaneous coronary intervention (PCI) compared to fibrinolytic therapy 
(FL) observed in selected patients with myocardial infarction and ST-elevation (STEMI) in 
randomized controlled trials (RCTs), can be replicated in “real-life” patients within “real-
life” contexts.  “Real-life” patients with STEMI are generally older and with more co-
morbidity than patients enrolled in RCTs (38,193).  Primary PCI is complex, time and 
labor-intensive, and available at only a minority of hospitals in the “real-life” context 
(168,169,199).  Additionally, adverse effects of reperfusion therapy (RT) may not be 
adequately characterized by RCTs due to the highly selected patient population (38,193-
197).  Moreover, since the follow-up of most RCTs are often limited in duration (i.e., ≤1 
year) (81), it remains unclear whether the reduction in mortality with primary PCI 
compared to FL persists with longer follow-up (81). Finally, the survival benefit of primary 
PCI might have been over-estimated due to many methodological flaws of several previous 
meta-analyses and RCTs (198).  Due to all the above reasons, additional information from 
observational studies may improve the inference based on only RCTs (199-201).  
• Time delay to RT is the main modulator of survival benefits of both primary PCI and 
FL (2).  Both RT strategies become less effective after prolonged delays (2).  Furthermore, 
patients with STEMI are at the highest risk of dying during the earliest hours (76).  
Therefore, it is crucial that delays to RT be minimized as much as possible.  Considering 
the inclement climate and vast geography in Canada, timely provision of RT can be 
problematic for a large number of patients with STEMI (67,169).   
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Since prehospital fibrinolysis (PHL) can be initiated at time of the first contact 
between the paramedics and patients with STEMI, it can be a remarkable time-saving RT 
strategy.  PHL has been implemented successfully in several European jurisdictions (6,73).  
Due to lack of physicians and nurses in North America (6), it remains unclear whether PHL 
can be adapted to the Canadian context (203-204).  Detailed appraisal of the infrastructure, 
processes and outcomes of effective PHL programs may assist stakeholders to initiate PHL 
programs in Canada.  
Optimal management of patients with acute coronary syndromes (ACS) requires early 
and accurate risk stratification of these patients (189-190).  Physician assessment is 
subjective, potentially biased and less precise than formal ACS risk scores (191).  However, 
due to their complexity, currently available risk scores are infrequently used (190). 
Physicians tend to rely on their clinical judgement only and often under-estimate the 
mortality risk of patients with ACS (191).  Consequently, high-risk patients with ACS may 
not be able to receive promptly life-saving interventions.  A straightforward risk score 
which can be easily memorized, calculated by hand and requires only simple clinical 
variables, would be of great use for early risk stratification of patients with ACS. 
 
In this dissertation, I will address these three knowledge gaps by: 
• Performing Bayesian meta-analyses of RCTs and observational studies to compare 
short and long-term mortality reductions of primary PCI and Fl.  Bayesian meta-analysis 
accounts for heterogeneity between studies and allows smaller studies to borrow strength 
from the overall estimate (115-116).  For this reason, large studies with biases would have 
less impact on the summary estimate with Bayesian meta-analysis, than with conventional 
random- and fixed-effect models.  Additionally, meta-analysis of observational studies 
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will provide in-depth evaluation of the safety and effectiveness of primary PCI and FL in 
“real-life” patients within “real-life” context. (Manuscript 1) (66). 
•  Surveying of several international and national PHL programs to provide an 
understanding of the pre-hospital infrastructure required for PHL implementation in 
Canada.  (Manuscript 2) (67). 
• Developing a simple risk score that can accurately predict short and long-term 
mortality in patients with ACS (Manuscript 3) (205).  Availability of a simple risk score 
will allow for early risk stratification and tailored management of patients with ACS.  
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Chapter 4. 
 
Manuscript 1 
 
4.1 Preamble 
  
Although primary percutaneous coronary intervention (PCI) is more effective than 
fibrinolytic therapy (FL) in restoring flow in the occluded coronary artery of patients with 
acute myocardial infarction and ST-elevation (STEMI) (2), accessibility to primary PCI is 
limited with only a fraction of hospitals able to deliver this reperfusion therapy (RT) in a 
timely manner (166,168-169).  Prolonged delays to primary PCI may attenuate the survival 
benefit (2,76,78).    
The safety and efficacy of primary PCI and FL have been evaluated in 25 
randomized controlled trials (RCTs) (12-37).  Considering the relatively small sample size 
and limited power of most RCTs, survival benefits of the two reperfusion strategies can 
only be reliably evaluated in meta-analyses (198).   Of the 21 published meta-analyses of 
RCTs that compared primary PCI and FL (37,92-112), only four (94, 103,100,110) used 
random-effects models.  All other meta-analyses used fixed-effects models since 
heterogeneity testing suggested lack of variation between trials (37,92-93,95-99,101-109).  
However, heterogeneity testing are poorly sensitive and may fail to detect significant 
differences between RCTs (112,114-115).  Fixed-effects models may over-estimate the 
difference in efficacy between treatment arms, if they do not take the heterogeneity 
between RCTs into account (112,114-115).   
In considering inter-RCT variation, random-effects models commonly provide more 
conservative estimates of the difference in efficacy between treatment arms (113-115).  In 
addition to conventional random-effects models, Bayesian hierarchical random-effects 
models allow individual studies to borrow strength from the global estimate (115-116).  
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Consequently, small well-designed studies can contribute more to the global estimate (115-
116) and studies with large sample sizes but with sub-optimal designs have less impact on 
the global estimate (115-116).   
Furthermore, there is no prior systematic review of observational studies.  Although 
RCTs are generally considered the gold standard for evaluation of efficacy, observational 
studies provide invaluable information about the effectiveness and safety of RT 
administration in “real-life” patients in “real-life” context (39,195-197).  In the first 
manuscript of this thesis, I systematically reviewed all published observational studies that 
compared primary PCI to FL (66).  This systematic review of effectiveness and safety of 
RT in “real-life” patients in “real-life” context contributes unique insights into the external 
validity of previous RCTs.   
4.2 Methods 
4.2.1 Literature search  
I searched the following databases (with no language restrictions) using the 
following keywords: “angioplasty”, “fibrinolysis”, “thrombolysis”, “FL”, “acute 
myocardial infarction”, “percutaneous coronary intervention”, “reperfusion therapy”, 
“coronary stent” as keywords to identify RCTs and observational studies that compare 
primary PCI and FL in STEMI:  BIOSIS, Cinahl, Embase, Pubmed, Web of Science, 
Cochrane Library, health technology assessment agencies and Current Contents.  In 
addition, I hand-searched the reference lists of published articles to ensure retrieval of all 
pertinent studies on STEMI.   
4.2.2 Inclusion of studies  
I included only studies that used full-dose commercially approved FL such as 
streptokinase, urokinase, and fibrin-specific agents such as tissue plasminogen activators, 
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tenecteplase, and reteplase.  In addition, the selected studies had to report mortality for 
both treatment arms (primary PCI and FL) separately.  Finally, all observational studies 
retained had to meet the quality requirements suggested by Concato et al. (39) such as 
inclusion of concurrent rather than historical controls, and these studies should also have 
clearly defined inclusion criteria.   
4.2.2 Exclusion of studies  
I excluded studies in which the investigators used experimental FL agents (i.e., 
not commercially approved) or intra-coronary administration of FL (non-conventional 
method of administration).   In addition, I excluded studies presented or published as 
abstracts or as conference proceedings.    
4.2.3 Definition of endpoints  
The endpoints of interest were short and long-term all-cause mortality, reinfarction 
and stroke. All-cause mortality was selected as the primary endpoint since it is the most 
objective and reliable endpoint (82).  I elected not to use cardiovascular mortality since this 
endpoint depends on subjective classification of mortality causes and may be more prone to 
ascertainment bias.  All endpoints were analyzed as distinct events rather than as a 
composite endpoint comprising multiple events.  The approach of combining endpoints is 
suboptimal due to equal weights attributed to endpoints with unequal clinical relevance (i.e. 
death would have an equal weight to more benign endpoint such as re-hospitalization) (82).   
4.2.4 Data abstraction  
Two independent observers (i.e., I and SP (i.e., the second author of this manuscript) 
completed data abstraction and disagreements were resolved by consensus.   
4.2.5 Evaluation of study quality  
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 I assessed the qualities of the RCTs and observational studies retained in conformity 
with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines (206). I completed detailed qualitative assessment of the internal and external 
validity and potential biases for each study.  I elected not to complete a quantitative 
evaluation of study quality by scales since inappropriate scoring of study quality may result 
in erroneous adjustment of the overall treatment effect (207). 
4.2.6 Statistical methods  
Methodology of meta-analysis  
Meta-analysis can be undertaken using either a frequentist (114) or Bayesian 
approach (115-116). In a frequentist meta-analysis, the summary statistic is calculated as a 
weighted average of the treatment results pooled across studies (114).  The weights reflect 
the amount of information from each study (114).   
Frequentist meta-analysis can be undertaken either with a fixed-effects model or 
with a random-effects model (113). In a fixed-effects model, the weight of each study is 
determined by the precision of the study (115). It is assumed that the true treatment effect is 
the same across studies and that variation among studies is entirely due to chance.  In a 
random-effects model, the effect sizes are assumed to differ between studies.  The effects 
sizes effects are normally distributed with mean and variance (Ʈ2) in random-effects 
models (115).  The weight of each study is determined as Wi=1/(SE of the treatment 
effect)2+ Ʈ2 (115).  In general, the random-effects models provide more conservative 
estimates of the treatment effects with wider confidence intervals than the fixed-effects 
models (113-115).  The Wi (1/SE of the treatment effect)2+ т2) varies less across studies in 
the random-effects models than the Wi (1/(SE of the treatment effect)2 of the fixed-effects 
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models.  Consequently, smaller studies are given more weight in a random-effects model 
than in a fixed-effects model (113-115). 
The application of a fixed-effects model is only valid in the absence of excess 
variation in the results across studies (113-115).  Statistical tests of homogeneity (also 
called tests of heterogeneity) are generally used to evaluate homogeneity of results across 
studies (113).  However, these tests often have poor sensitivity for significant inter-study 
variation, especially in meta-analyses of a small number of studies (112).  Therefore, the 
potential false-negativity of the test of homogeneity (or heterogeneity) and the incorrect 
application of a fixed-effects model should always be considered (112).  By contrast, if 
there is statistical evidence of heterogeneity, the inter-study variation is beyond random 
variation and cannot be ignored (112-115).  In this circumstance, random-effects models 
should be used to pool findings from previous studies (113-115).   
Bayesian meta-analysis is based on the Bayesian theorem that allows for integration 
of prior beliefs (115).  Bayesian statisticians specify a prior probability distribution, based 
on a prior belief, such as expert opinion of the treatment effect (115-116).  The summary 
estimate also called the posterior probability distribution results from incorporation of the 
prior probability distribution into the pooled data (115-116).  Thus, Bayesian methodology 
allows for incorporation of different sources of evidences such as expert opinions in 
addition to the studies included in the models (115-116).   Non-informative priors can be 
used to analyze data without consideration of prior beliefs, (i.e. the pooled estimates 
derived mainly from the findings of previous studies, and without consideration of expert 
opinion) (115-116).   
Bayesian modeling can be either random or fixed-effects (115-116). Similar to the 
frequentist approach, Bayesian hierarchical random-effects meta-analysis takes the intra 
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and inter-studies variation into account (115-116). In addition, Bayesian meta-analysis 
allows for each study to borrow strength from the overall estimate (115-116).  In other 
words, a study with markedly different results from the other studies would have less 
impact on the overall estimate, in a Bayesian model compared to other types of meta-
analyses (116).    
All statistical meta-analyses methods have their own advantages and disadvantages 
(112-115).  Since it is unlikely that the effect of primary PCI and FL is similar across 
studies, a fixed-effects model is not appropriate.   Bayesian random-effects modeling is a 
more suitable approach since it takes the inter-trial variation into account (115-116). 
I completed separate meta-analyses for each endpoint, for RCTs and observational 
studies separately.  In these models, the probability of an event within each group in each 
trial was assumed to follow a binomial distribution (116).  The models allowed for the 
probability of an event to vary both between treatment arms within each study, and between 
studies (116).  The logarithms of the odds ratios (ORs) were assumed to have a normal 
distribution (116).  The means of the normal distribution of the logarithm of the odds ratios 
across studies represented the average effect across studies, and the variances represented 
the variability between studies (116).   
I selected non-informative prior distributions for all parameters of interest, so that 
the results would primarily reflected the findings from included studies, without 
considering prior knowledge or subjective beliefs (116).  Sensitivity analyses varying the 
prior distributions did not change posterior inferences substantially.  Consequently, the 
estimates of odds ratios and 95% credible intervals were not substantially affected by the 
choice of a prior distribution.  
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I computed inferences by using a Gibbs sampler algorithm (WinBUGS software 
version 1.4.2, MRC Biostatistics Unit, Cambridge, UK).  The final summary statistics were 
based on 120,000 iterations. The forest plots were completed with R 2.4.1 software 
(www.r-project.org/). The numbers needed to treat was 1/absolute risk difference for each 
outcome of interest.    
Evaluation of publication bias  
Publication bias is the “tendency of authors and editors to publish studies with 
positive results” (89).  Publication bias can also occur from “size bias” when studies with 
larger sample sizes are preferentially published relative to smaller studies (89).  Since the 
quality of the study design does not necessarily relate to the sample size of the study, a 
meta-analysis may be flawed by lack of inclusion of small un-biased studies and/or 
inclusion of large and biased studies (112-115).  Another type of publication bias is 
“suppression bias” which occurs when studies are prevented from being published if the 
results may be harmful to the sponsor’s financial interest (208). “Language bias” may 
results from the lack of inclusion of studies published in languages other than English 
(208).  
I tested for publication bias by constructing funnel plots for RCTs and observational 
studies separately.  Funnel plots are plots of the treatment effects on the horizontal axis 
against a measure of the studies sizes on the vertical axis (114,208).   The results of small 
studies are generally less precise and are more scattered around the overall estimate 
(114,208).  The results of larger studies are more precise and concentrate around the overall 
estimate (114,208).   This gives the appearance of an inverted funnel (114,208).  In the 
event of non-publication of small negative studies, the funnel plot will be asymmetrical 
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because of lack of small studies on one side of the funnel plot (114,208).  Funnel plots are 
performed with MIX (www.mix-for-meta-analysis.info).  (Appendix 1).  
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Contributions of Co-Authors 
Dr Huynh and Perron completed the literature search, read the abstracts, selected the 
studies to be included in the meta-analyses, read all selected manuscripts in whole, 
completed data abstraction and cross-validated the abstracted data. 
Dr Huynh completed all data analyses including random-effects Bayesian modeling, forest 
plots and funnel plots under the supervision of Dr Lawrence Joseph.   
Dr Lawrence Joseph supervised the statistical analyses, reviewed and provided statistical 
inputs into the draft and final manuscript. 
Drs O’Loughlin, Labrecque, Tu and Theroux reviewed and provided inputs into the study 
design, results and manuscript. 
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Structured abstract  
 
Background:  Published meta-analyses comparing primary percutaneous coronary 
intervention with fibrinolytic therapy in patients with ST-segment elevation myocardial 
infarction include only randomized controlled trials. We aim to obviate the limited 
applicability of randomized controlled studies to real-world settings by undertaking meta-
analyses of both randomized controlled trials (RCT) and observational studies. 
Methods and Results: We included all RCTs and observational studies, without 
language restriction, published up to 1 May 2008.  We completed separate Bayesian 
hierarchical random-effect meta-analyses for 23 randomized controlled studies (8,140 
patients) and 32 observational studies (185,900 patients). 
Primary percutaneous coronary intervention (PCI) was associated with reductions 
in short-term (≤6-week) mortality of 34% (Odds Ratio (OR): 0.66; 95% Credible Interval 
(CrI): 0.51-0.82) in randomized trials, and 23% lower mortality (OR: 0.77, 95% CrI: 
0.62-0.95) in observational studies.  Primary PCI was associated with reductions in stroke 
of 63% in RCTs and 61% in observational studies.  At long-term follow-up (≥1 year), 
primary PCI was associated with a 24% reduction in mortality (OR: 0.76, 95% CrI: 0.58-
0.95) and a 51% reduction in reinfarction (OR: 0.49, 95% CrI: 0.32-0.66) in RCTs.  
However there was no conclusive benefit of primary PCI at long-term in the 
observational studies 
Conclusions:  Compared to fibrinolytic therapy, primary percutaneous coronary 
intervention was associated with short-term reductions in mortality, reinfarction and 
stroke in ST-segment elevation myocardial infarction. Primary PCI was associated with 
long-term reductions in mortality and reinfarction in RCTs, but there was no conclusive 
evidence for a long-term benefit in mortality and reinfarction in observational studies. 
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Condensed abstract 
We conducted separate hierarchical Bayesian random-effects meta-analyses of all 
randomized controlled trials and observational studies that compared primary 
percutaneous coronary intervention with fibrinolytic therapy (published up to 1 May 
2008).  Primary percutaneous coronary intervention was associated with reductions in 
short-term mortality, reinfarction and stroke in both types of studies.  The benefits in 
mortality and reinfarction reductions associated with primary PCI remained at long-term 
follow-up in the randomized controlled studies.  There was no conclusive long-term 
benefit associated with primary percutaneous coronary intervention in the observational 
studies. 
 
Abreviations 
AMI:  Acute Myocardial Infarction 
CrI:    Credible Intervals 
OR:   Odds Ratio 
NNT: Numbers Needed to Treat 
PCI:   Percutaneous Coronary Intervention 
Q1:Q3:  First quartile, third quartile  
RCT:  Randomized Controlled Trial 
STEMI:  ST Segment Elevation Myocardial Infarction 
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Introduction 
Several randomized controlled trials (RCTs) (1-23) show that primary PCI is 
associated with reductions in mortality, reinfarction and stroke compared to fibrinolytic 
therapy. However many aspects of reperfusion therapy might not be optimally assessed in 
RCTs.  First, the benefit of primary PCI may not be replicable under sub-optimal 
conditions such as at low-volume and less expert PCI centers (24), outside regular 
working hours, or after lengthy inter-hospital transfer. Second, use of rescue or elective 
PCI was limited (less than 20%) in several RCTs (1, 8, 11-12,14, 16-17,20-22), while 
rescue or elective PCI is generally performed as indicated in the real-world.  Furthermore, 
patients with ST-segment elevation myocardial infarction (STEMI) enrolled in RCTs are 
generally younger with fewer co-morbid conditions than patients in the “real-world” (25).  
Therefore extrapolation of the safety and effectiveness of primary PCI and fibrinolytic 
therapy observed in RCTs to the “real-world” STEMI population might not be entirely 
appropriate.  Previous meta-analyses included only RCTs.  We aim to obviate the 
limitations of these analyses by examining results from observational studies, in addition 
to those of RCTs. We also include recently published data from several RCTs that were 
not considered in previous meta-analyses. 
Methods 
Search strategy  
 We retrieved RCTs and observational studies that compared primary PCI and 
fibrinolytic therapy in STEMI from the following databases: BIOSIS, Cinahl, Embase, 
Pubmed, Web of Science, Cochrane Library, health technology assessment agencies and 
Current Contents (up to 1 May 2008) (no language restriction), using the following 
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keywords: “angioplasty”, “fibrinolysis”, “thrombolysis”, “fibrinolytic therapy”, “acute 
myocardial infarction”, “percutaneous coronary intervention”, “reperfusion therapy”, 
“coronary stent”, “ treatment” and “management”.  In addition, we hand-searched the 
references of published articles to ensure identification of all published STEMI trials.   
Inclusion criteria 
 Only studies that used full-dose commercially approved fibrinolytic therapy such 
as streptokinase, urokinase, and fibrin-specific agents such as tissue plasminogen 
activators, tenecteplase, and reteplase were retained for analysis.  We retained only 
studies that reported results for both treatment arms (primary PCI and fibrinolytic 
therapy).  Finally, the observational studies retained had to fulfill the quality requirements 
suggested by Concato et al. (26) including: inclusion of concurrent rather than historical 
controls, clearly defined inclusion criteria and time of entry into the study.   
Exclusion criteria 
 We excluded studies that used facilitated PCI, experimental fibrinolytic agents 
(other than the agents listed above), or intra-coronary administration of fibrinolytic 
therapy as well as studies that enrolled mainly patients with contra-indications to either 
fibrinolytic therapy or primary PCI.  For studies that compared primary PCI, facilitated 
PCI and fibrinolytic therapy (2,16,22), we excluded patients who underwent facilitated 
PCI from the analysis.  We also excluded studies presented or published only as abstracts 
or conference proceedings, because detailed appraisal of the methodology and potential 
biases was not possible.  
Endpoints  
All endpoints were analyzed as distinct events rather than as a composite endpoint 
comprising multiple events.  The latter approach can be suboptimal because of equal 
54 
 
54 
 
contributions to the composite endpoint by endpoints with unequal clinical relevance 
(27).  Intra-cranial bleeding was compiled as stroke and therefore excluded from major 
bleeding.  Major bleeding included all hemorrhagic complications that were severe or 
life-threatening or required transfusion. Short-term endpoints included all events up to 6 
weeks after the index STEMI. Long-term endpoints included all events that occurred at 
least one year after the STEMI.   
Study quality 
We critically appraised the quality of the RCTs and observational studies in 
conformity with the CONSORT and the MOOSE guidelines (28-29). We elected not to 
use scales to evaluate the quality of each study since this approach is controversial with 
potentially inappropriate adjustment of the treatment effects and marked variation in 
treatment effects depending on the scale used (30).   
Data extraction 
Two reviewers (TH and SP) independently selected studies for inclusion, 
extracted data, and evaluated the quality of each study. Disagreements were resolved by 
consensus between the two reviewers.   
Statement of Responsibility 
The first author (TH) had full access to and take full responsibility for the 
integrity of the data.  All authors have read and agree to the manuscript as written. 
• Statistical methods 
We completed separate meta-analyses for each endpoint, for RCTs and 
observational studies separately.  Since it was unlikely that the effect of primary PCI and 
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fibrinolytic therapy would be similar across studies due to differences in study design and 
patient characteristics, a fixed-effect model was not appropriate.  Therefore we used a 
Bayesian hierarchical random-effects model to take inter-trial variation in treatment 
effects into account (31).    
In our models, the total number of events within each group in each trial was 
modeled as a binomial random variable.  The models allowed for the probability of an 
event to vary both between treatment arms within each study, and between studies.  The 
logarithms of the odds ratios were assumed to have a normal distribution.  The mean of 
the normal distribution of the logarithm of the odds ratios across studies represented the 
average effect across studies, and the variance represented the variability between studies.   
Bayesian analysis allows integrating new information into existing knowledge.  
Substantive prior knowledge can be included into Bayesian analysis through the choice of 
a prior distribution.  Since we wanted our results (i.e., the posterior distributions) to 
primarily reflect data from previous studies, we selected non-informative prior 
distributions for all parameters of interest.  These included normal densities (mean: 0 and 
tau=0.00001 (variance of 105) for the logarithm of the odds ratios, and sigma (sigma= 
uniform on the interval (0,2)).    Sensitivity analyses varying the prior distributions for 
sigma and a gamma prior distribution (0.001,0.001) did not change posterior inferences 
substantially.  Therefore, our estimates of odds ratios and 95% credible intervals were not 
greatly affected by our choice of a prior.  
Inferences were calculated using a Gibbs sampler algorithm as implemented 
through WinBUGS software (version 1.4.2, MRC Biostatistics Unit, Cambridge, UK).  
To ensure convergence of the Gibbs sampler algorithm, three Markov Monte-Carlo 
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chains were run and convergence was assessed after 60,000 iterations.  The final 
summary statistics were based on 120,000 iterations, 100,000 of them for burn-in. The 
forest plots were completed with R 2.4.1 software (www.r-project.org/). We examined 
for potential publication bias with funnel plots, fail-safe N and trim and fill (www.meta-
analysis.com). Sensitivity analyses were performed with non-Bayesian statistical 
methods, random-effect restricted maximum likelihood method (SAS 8.0) and random 
effects model (DerSimonian and Laird) (NCSS-2007).   The results were essentially 
similar to those obtained by Bayesian hierarchical meta-analyses.  
Results  
Figure 1 describes the selection of studies into the analysis.  Twenty-three RCTs (1-
23) and 32 observational studies (24, 31-62) were retained.  The mean age of patients 
enrolled ranged from 57 to 80 years in the RCTs and from 57 to 91 years in the 
observational studies.  Two RCTs (2,4) and 7 observational studies reported pre-hospital 
administration of fibrinolytic therapy (23,35,39,49,61-62).  Fibrin-specific agents were 
used primarily in 16 RCTs (1-4,6-12,14-15,19-20, 22) and 11 observational studies 
(24,33,35,37,41,43-44,48,53,57,61).  (Appendix Tables 1 and 2) 
Primary PCI was associated with an approximate 34% short-term reduction in 
mortality (OR: 0.66; 95% CrI: 0.51-0.82) in RCTs (Figure 2), and an approximate 23% 
lower mortality in observational studies (OR: 0.77, 95% CrI: 0.62-0.95) (Figure 3). There 
was no conclusive difference in mortality in the meta-analysis of observational studies 
that used pre-hospital fibrinolytic therapy (23,35,39,49,61-62). Estimate of the difference 
in mortality between primary PCI and pre-hospital fibrinolytic therapy could not be done 
with certainty since there were only two RCTs that used pre-hospital fibrinolysis (2,4). 
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In RCTs, primary PCI was associated with a 24% reduction in long-term mortality 
(OR: 0.76, 95% CrI: 0.58-0.95) (Figure 4).  However, in observational studies, there was 
no conclusive difference between the two reperfusion strategies in long-term mortality 
(OR: 0.88, 95% CrI: 0.68-1.18) (Figure 5). Reductions in short-term reinfarction of 65% 
and 53% were observed in RCTs and observational studies, respectively (Table 1). An 
approximate 51% reduction associated with primary PCI in long-term reinfarction was 
noted in RCTs, while there was no conclusive difference in reinfarction between 
treatments in the observational studies (Table 1). Primary PCI was associated with a 60% 
reduction in stroke in both RCTs and observational studies (Table 1). Although 
inconclusive due to the limited number of studies available, the risk estimates were 
consistent with a possible increase in major bleeding associated with primary PCI (Table 
1). 
Absolute risk reductions in short-term mortality with primary PCI were 
approximately 2.2% (95% CrI: 1.3%-3.2%) in RCTs, and 1.1% (95% CrI: 0.4%-1.5%) in 
observational studies (Table 2).  Absolute risk reductions in short-term reinfarction were 
approximately 4.5% in RCTs, and 2.9% in observational studies.  Absolute reductions in 
stroke were approximately 1.2% in RCTs, and 0.6% in observational studies.  At long-
term follow-up, primary PCI was associated with absolute reductions in long-term 
mortality of 3.5% (95% CrI: 0.7-6.4) and in reinfarction of 3.4% (95% CrI: 1.6-5.9) in 
RCTs, without conclusive evidence for reductions in long-term mortality and reinfarction 
in observational studies.  
The numbers needed to treat (NNT) to prevent one short-term death with primary 
PCI was 45 in RCTs and 91 in observational studies (Table 2). The NNT was 29 in RCTs 
to prevent one long-term death.  More specifically, for 100 patients treated with primary 
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PCI, in conditions similar to those in the RCTs, there would be two deaths and five 
reinfarctions prevented at short-term; three deaths and five reinfarctions prevented in the 
long-term.  For 100 patients treated with primary PCI, in conditions similar to those in 
observational studies, one death and three reinfarctions would be prevented in the short-
term, with no conclusive long-term benefit.  For stroke reduction, approximately one 
event would be prevented in 100 patients treated with primary PCI in conditions similar 
to those in the RCTs, while only one stroke would be prevented in approximately 200 
patients treated with primary PCI in conditions similar to those in the observational 
studies. 
Discussion 
Our meta-analyses improve on previous systematic reviews by including short-
term results from three recent RCTs (2, 19-21) and inclusion of observational studies 
(28,32-62).  Our study incorporates events at 1-year and includes long-term results from 
five RCTs that were not considered in earlier reviews (data at 1-year from Dobrycski and 
PRAGUE-1 (21,63), at 2-year from the PAMI-1 (64) at 3-year from DANAMI-2 (65), at 
5-year from PRAGUE-2 (66) and at 8-year from the Zwolle Study (67). Given the 
marked heterogeneity in study designs and patient populations across studies, our 
random-effects hierarchical Bayesian meta-analyses are more appropriate models (37) 
than the fixed-effects models.   
Several biases may affect the internal validity of RCTs, including lack of central 
randomization and a blinded adjudication committee, both of which may affect the 
integrity of randomization and objective ascertainment of endpoints.  Only 10 RCTs 
specified use of central randomization (1, 3-5,10,16-17,20,22,23).    Outcome 
adjudication by a blinded committee was mentioned in only 10 RCTs (1-2,4-6,9-12,15). 
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Observational studies are susceptible to many biases including among others, 
selection and confounding biases.  Observational studies that exclude patients who did 
not undergo a planned primary PCI may be subject to selection bias. Only three 
observational studies included all patients assigned to primary PCI regardless of whether 
or not they underwent successful PCI (24,38-39). 
 Confounding bias may occur in observational studies when patient characteristics 
affect the treatment received and the outcomes.  Patients who received fibrinolytic 
therapy were older than patients who received primary PCI in three observational studies 
(34-35,40).  There were more patients with anterior STEMI, heart failure or cardiogenic 
shock in the primary PCI group in six studies (34,39-41,45,48), and in patients who 
received fibrinolytic therapy in two studies (33,35).  Primary PCI patients received more 
optimal medical therapy and coronary intervention, and in addition were more likely to be 
treated at high-volume hospitals than patients who received fibrinolytic therapy 
(35,41,44,48).   
 The internal validity of both RCTs and observational studies may be affected by 
differential loss to follow-up in the treatment groups.  With the exception of one study 
(64) that reported high attrition (16%), long-term follow-up was almost complete in most 
RCTs.  Five observational studies reported at least 95% long-term follow-up (33-
34,39,45,62).  Our risk estimates remained virtually unchanged when restricted to studies 
with optimal follow-up. 
The applicability of results from RCTs to “real-world” setting is generally limited. 
Several RCTs excluded elderly patients (7,13-14,21,22), patients with renal disease (3-
4,10,12), those in cardiogenic shock (1,4,7,9,14,19,22), patients with Killip class 2 
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(8,18,20,23) and patients with left bundle branch block (1,6,8,18,21) so that their results 
may not be applicable to these high-risk patient groups.   
The long-term attenuation of the early reductions in mortality and reinfarction 
associated with primary PCI may be due to optimal long-term medical therapy that may 
have delayed the long-term progression of coronary artery disease equally in both 
treatment arms. The reduced magnitudes of risk reductions associated with primary PCI 
in observational studies compared to those in RCTs might reflect “real-world” practice. 
Greater use of in-hospital PCI (≥30%) following fibrinolytic therapy in observational 
studies (24,35,41,43-44,55,62) may partially explain the smaller reductions in short-term 
mortality and reinfarction associated with primary PCI.  In the “real-world”, primary PCI 
may also be less successful when performed in less than optimal conditions.   In 
observational studies, the lack of conclusive long-term benefits with primary PCI may be 
explained by optimal medical therapy and/or the judicious use of coronary interventions 
in patients who received fibrinolytic therapy.   
Limitations  
These meta-analyses have several limitations that warrant mention.  First, the 
comparison of primary PCI with pre-hospital fibrinolysis could not be ascertained with 
certainty due to the small number of studies that used this reperfusion strategy.   The 
efficacy and safety of pre-hospital fibrinolysis compared to primary PCI may be better 
evaluated in future large studies.  Second, the greater use of thienopyridines in primary 
PCI than in the fibrinolytic therapy arm might have partially confounded the results.  The 
mortality difference between primary PCI and fibrinolytic therapy may be attenuated with 
more systematic administration of thienopyridines following fibrinolytic therapy.  On the 
other hand, recent technological advances in primary PCI may further increase the 
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mortality and reinfarction benefits associated with primary PCI.  Third, the validity of our 
meta-analysis of long-term mortality in observational studies was potentially limited by 
the lack of long-term data from the large observational studies NRMI-3/4 (56).  
Nonetheless, it would be unlikely that long-term data from NRMI-3/4 would modify our 
results since there was no short-term mortality difference between the two treatment arms 
in this study.  Fourth, our estimate of long-term mortality may have been influenced by 
the large observational RIKS-HIA study (35).  However, sensitivity analyses excluding 
the study RIKS-HIA showed essentially similar results with no conclusive difference in 
long-term mortality between the two treatment arms. Finally, reports with positive 
findings are more likely to be reported, published and cited (68).  However, the lack of 
asymmetry in the funnel plots suggests that we did not miss major negative studies. 
Conclusions 
 Compared to fibrinolytic therapy in STEMI, primary PCI was associated with short-
term reductions in mortality, reinfarction and stroke in both RCTs and observational 
studies and with long-term reductions in reinfarction and mortality in RCTs.  There was 
no conclusive difference in long-term mortality and reinfarction between primary PCI and 
fibrinolytic therapy in the observational studies reviewed. The potential benefit of pre-
hospital fibrinolysis compared to primary PCI cannot be reliably ascertained from this 
review.  
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Figures legends 
 
• Figure 1a. QUOROM flow diagram of randomized controlled studies 
Figure 1b. QUOROM flow diagram of observational studies 
• Figure 2. Bayesian forest plot of all-cause short-term mortality in randomized 
controlled studies 
• Figure 3. Bayesian forest plot of all-cause short-term mortality in observational 
studies 
• Figure 4. Bayesian forest plot of all-cause long-term mortality in randomized 
controlled studies 
• Figure 5. Bayesian forest plot of all-cause long-term mortality in observational 
studies 
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Figure 1a.  QUOROM flow diagram of randomized controlled studies 
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Figure 1b. QUOROM flow diagram  of observational studies 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant studies that compared  primary PCI and 
fibrinolytic therapy identified and screened, 
 n=2 101  
Observational studies retrieved for 
more detailed evaluation 
n = 423
Studies excluded, with reasons:  
1. Incomplete or missing survival data for  
both fibrinolytic therapy and primary PCI, 
n=352 
2.Non-concurrent treatment groups, n=1 
3. Primary angioplasty facilitated with 
fibrinolytic therapy,n=4 
4. Included mainly patients with contra-
indications to either fibrinolytic therapy or 
primary PCI, n=2 
5.Intra-coronary fibrinolytic therapy, n=1 
6. Non-commercially approved fibrinolytic 
agent: n=1 
Observational studies included in the meta  
n=32 with data on survival 
n=15 with data on reinfarction, 
n=15 with data on stroke 
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Table 1.  Meta-analyses of major adverse outcomes 
 
Randomized controlled trials 
 
Outcome N of studies N of patients Odds ratios 
(95% credible intervals)
Short-term mortality 23 8 140 0.66 (0.51-0.82)
Long-term mortality 11 4 320 0.76 (0.58-0.95)
Short-term reinfarction 22 7 937 0.35 (0.24-0.51)
Long-term reinfarction 9 4 121 0.49 (0.32-0.66)
Stroke 21 7 932 0.37 (0.21-0.60)
Major bleeding 15 4 624 1.40 (0.88-2.00)
Observational studies 
 
Outcome N of studies N of patients Odds ratios 
(95% credible intervals)
Short-term mortality 29 180 877 0.77 (0.62-0.95)
Long-term mortality 12 54 571 0.88 (0.60-1.18)
Short-term reinfarction 15 45 087 0.47 (0.32-0.67)
Long-term reinfarction 4 32 181 0.58 (0.29-1.21)
Stroke 15 35 158 0.39 (0.29-0.61)
Major bleeding 10 19 459 1.30 (0.37-4.42)
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Table 2.  Absolute risk reductions and numbers needed to treat 
Outcome % of events in the 
fibrinolytic therapy 
group 
Absolute risk reductions,% 
(95% Credible Intervals) 
 
Numbers needed to treat 
with primary PCI to 
prevent one event 
RCT Observational 
studies 
RCT Observational 
studies 
RCT Observational 
studies 
Short-term 
mortality 
7.1 7.3 2.2 
(1.3-3.2)
1.1 
(0.4-1.5)
45 
(31-77) 
91 
(67-250)
Short-term 
reinfarction 
6.7 9.4 4.5 
(3.6-5.4)
2.9 
(1.3-4.8)
22 
(19-28) 
35 
(21-77)
Long-term 
mortality 
16.7 11.7 3.5 
(0.7-6.4) 
1.1 
(3.0 reduction to 
2.4 increase)
29 
(16-143) 
NA
Long-term 
reinfarction 
9.4 5.8 3.4 
(1.6-5.9) 
2.4 
(4.0 reduction  to 
5.7 increase)
29 
(17-63) 
NA
Stroke 1.9 0.8 1.2 
(0.8-1.5)
0.6 
(0.5-0.7)
83 
(67-125) 
166 
(143-200)
RCT:  Randomized Controlled Trial 
PCI:  Percutaneous Coronary Intervention 
NA:  Not applicable since there was no conclusive benefit with primary PCI  
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Chapter 5 
Manuscript 2 
5.1. Preamble 
The survival benefit of reperfusion therapy (RT) declines rapidly with prolonged 
time delays to restoration of flow in the occluded coronary artery (76).  Early RT 
administration, within the first hour of symptom onset of myocardial infarction with ST- 
segment elevation (STEMI), provides the greatest reductions in mortality and permanent 
heart damage (2,76).  Of the two available RT strategies, fibrinolytic therapy (FL) is more 
likely to be administered within the first hour of STEMI symptoms than primary 
percutaneous coronary intervention (PCI) (208).   
 The greatest reduction in delays to FL can be achieved with pre-hospital 
administration of fibrinolytic therapy (PHL) (208).  Although PHL has been widely 
implemented in Europe for more than a decade (6,73), it is available in two Canadian 
provinces only (Alberta and Nova-Scotia) (67).  Increased access to PHL can potentially 
save a large number of lives (208).   
 The limited availability of PHL in Canada is due to several obstacles including lack 
of trained paramedics, absence of pre-hospital ECG (162) and the high costs of drug 
acquisition (81).  Insights from existing emergency medical systems (EMS) that have 
already successfully delivered PHL may assist in the implementation of this RT in Quebec 
(67). The survey described in the second manuscript of this dissertation is the first to 
describe the infrastructure of several existing PHL programs as well as the mortality and 
major adverse outcomes of patients managed by each PHL program (67).   I also described 
the EMS organization required for rapid transportation of patients for primary PCI (67).  
The pre-hospital perspective, as described in the second manuscript, is complementary to 
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the evaluation of in-hospital RT described in the first manuscript (66).  Findings from these 
two manuscripts may assist health care professionals in their selection and optimization of 
RT for patients with STEMI.   
5.2. Methods 
5.2.1. Selection of PHL programs  
To identify pre-hospital systems of care that have delivered PHL, I retrieved RCTs 
and observational studies which evaluated PHL from the following databases: BIOSIS, 
Cinahl, Embase, Pubmed, Web of Science, Cochrane Library, health technology 
assessment agencies and Current Contents (up to 1 May 2008) with no language 
restriction, using the following keywords: “fibrinolysis”, “thrombolysis”, “fibrinolytic 
therapy”, “acute myocardial infarction”, “pre-hospital fibrinolytic therapy” and 
“reperfusion therapy”.  In addition, I hand-searched the references of all articles retrieved 
to assure identification of all PHL programs.  Finally, I contacted several cardiology 
experts in STEMI management to inquire about existing PHL programs in Europe and 
North America.   
I obtained 100% response from the leading investigators of the seven PHL programs 
contacted including those in England/Wales, France, Vienna and Sweden (Europe), 
Edmonton and Nova-Scotia (Canada) and Houston (United States).  
5.2.2. Affiliated PHL research programs and national registries 
All PHL programs contacted have affiliated research projects.  These include the 
Myocardial Ischemia National Audit Project (MINAP) in England/Wales (209), the French 
Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI) in France (145),  the 
Register of Information and Knowledge about Swedish Heart Intensive care Admissions 
(RIKS-HIA) in Sweden (120), the Vienna-STEMI Registry in Vienna (127), the Alliance 
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for Myocardial Infarction Care Optimization (AMICO) in Houston (5), the Vital Heart 
Response in Edmonton (210) and the Cardiovascular Health Nova Scotia Program in Nova 
Scotia (211).    
5.2.3. Data collection 
Population and geography data 
I obtained data on the territory and population served by the PHL programs 
surveyed from the official website of United Nations Statistics (212-213).  For jurisdictions 
other than countries, I extracted population and geography data for 2008, from websites 
describing national statistics (i.e., for England and Wales (Office for National Statistics of 
England) (214), for Nova Scotia and Edmonton (Statistics Canada) (215), for Vienna (City 
of Vienna Information Center) (216), and for Houston (the United States Census Bureau) 
(217).  Data on the number of hospitals, the proportion of hospitals with PCI facilities (PCI-
hospital), and the annual incidence of STEMI within each jurisdiction were provided by the 
leading investigators of each PHL program surveyed (67).   
Survey on pre-hospital resources 
 In August 2008, I emailed a self-administered questionnaire (Appendix 2) to the 
lead investigators of participating PHL programs.  The questionnaire collected data on pre-
hospital services available, as well as information on the infrastructure of the PHL program 
and how the program worked (i.e., its processes).  Questionnaires were completed by all 
lead investigators in April 2009 (Appendix 2).  I re-contacted respondents in June 2010 to 
inquire about recent modifications to the PHL programs. 
Outcome data 
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Investigators were asked to report aggregate outcome data since the initiation of the 
PHL program, and also for the most recent years 2005-08.   I could not obtain individual 
patient data from the PHL programs surveyed due to confidentiality issues. 
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The pre-hospital fibrinolysis experience in Europe and North America and 
implications for wider dissemination 
Structured Abstract 
Objectives 
The objective of this manuscript was to describe the infrastructure and processes of 
selected European and North American PHL programs.  A secondary objective is to report 
outcome data from the PHL programs surveyed.  
Background 
Despite its benefit in reducing mortality in patients with ST-segment elevation 
myocardial infarction (STEMI), pre-hospital fibrinolysis (PHL) remains under-used in 
North America.  Examination of existing programs may provide insights to help address 
barriers to the implementation of PHL.   
Methods The leading investigators of PHL research projects/national registries were 
invited to respond to a survey on the organization and outcomes of their affiliated PHL 
programs.   
Results 
PHL was successfully deployed in a wide range of geographical territories (Europe: 
France, Sweden, Vienna, England and Wales; North America: Houston, Edmonton and 
Nova Scotia) and was delivered by health care professionals of varying expertises. In-
hospital major adverse outcomes were rare, with mortality ranging from 3% to 6%, 
reinfarction from 2% to 5% and stroke less than 2%.   
Conclusion 
Combining formal protocols for PHL for some patients with direct transportation of 
others to a PCI-hospital for primary PCI would allow for tailored reperfusion therapy for 
93 
 
93 
 
patients with STEMI. Insights from a variety of international settings may promote 
widespread use of PHL and increase timely coronary reperfusion worldwide.  
Condensed Abstract 
Pre-hospital fibrinolysis had been successfully deployed in a wide range of 
geographical territories (Europe: France, Sweden, Vienna, England and Wales; North 
America: Houston, Edmonton and Nova Scotia) and delivered by health care professionals 
of varying expertises. In-hospital major adverse outcomes were rare with mortality ranging 
from 3%-6%, reinfarction from 2%-5% and stroke <2%.  Combining formal protocols for 
PHL for some patients with direct transportation of others to a PCI-hospital for primary 
PCI would allow for tailored reperfusion therapy for patients with STEMI. Insights from a 
variety of international settings may promote widespread use of PHL and increase timely 
coronary reperfusion worldwide.  
 Background 
   Timely reperfusion through the administration of fibrinolytic therapy (FL) or 
primary percutaneous intervention (PCI) is critical in the management of acute myocardial 
infarction with ST-segment elevation (STEMI) (1,2). Compared to in-hospital 
administration, pre-hospital administration of FL (PHL) allows for earlier treatment and 
better survival (3).  While  primary PCI is the preferred reperfusion therapy, PHL may be 
superior to primary PCI in reducing mortality in patients with STEMI who present early 
(i.e., less than 2 hours after onset of symptoms) (4-5).   For rural populations, PHL may be 
the only reperfusion strategy that can be provided in a timely manner (6).   
PHL requires a complex pre-hospital system of care to enable prompt and accurate 
recognition of STEMI and skilled management of life-threatening complications of PHL 
such as arrhythmia, major bleeding and stroke (6).   In spite of this complexity, PHL has 
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been endorsed by the European Society of Cardiology (8-10) and well established in 
Europe for over two decades (8-10).  In contrast, PHL is available in very few American 
and Canadian regions (11) despite the larger territories and high proportion of rural 
populations in these countries compared to Europe (11-13).      
Insights into the infrastructure and processes that support PHL care in Europe and 
North America may assist other jurisdictions to implement PHL systems of care. Based on 
the longer European experience, patients who received PHL in these regions are more 
likely to have more favorable survival and fewer major complications compared to patients 
treated by less experienced PHL programs.  Therefore, European PHL survival data may 
serve as an optimal benchmark for other PHL programs.  The   primary objective of this 
manuscript was to describe the infrastructure and processes of care in selected European 
and North American PHL programs.  The secondary objective was to report outcome data 
from the PHL programs surveyed.  
Methods 
Selection of PHL programs  
 We contacted cardiology experts in STEMI treatment to inquire about available 
PHL programs in Europe and North America.  We obtained 100% response from the 
leading investigators of the seven PHL programs contacted: England/Wales, France, 
Vienna and Sweden from Europe, Edmonton and Nova-Scotia from Canada and Houston 
(Texas) from the United States.  
Affiliated PHL research programs/national registries 
All participating PHL programs had affiliated research projects which included the 
Myocardial Ischemia National Audit Project (MINAP) in England/Wales (14), the French 
Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI) in France (15),  the 
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Register of Information and Knowledge about Swedish Heart Intensive Care Admissions 
(RIKS-HIA) in Sweden, the Vienna-STEMI Registry in Vienna, the Alliance for 
Myocardial Infarction Care Optimization (AMICO) in Houston, the Vital Heart Response 
in Edmonton and the Cardiovascular Health Nova Scotia Program in Nova Scotia.    
Data collection 
PHL may have different impacts on STEMI morbidity and mortality depending on 
the rural urban mix of the population served, and access to hospitals that can deliver 
alternate reperfusion therapy such as primary PCI. Most recent data relevant to each PHL 
program included in this study on the territory and population served were extracted from 
the official website of United Nation Statistics (available only for the year 2008) (16).   We 
defined “rural” as all “non-urban” regions with a population of less than 1000 persons, and 
a population density less than 400 persons per km2 (Organisation for Economic Co-
operation and Development’s (OCDE) definition (17). For jurisdictions other than 
countries, we extracted population and geography data in 2008 from the national statistical 
websites (i.e., for England and Wales (Office for National Statistics of England (18), for 
Nova Scotia and Edmonton (Statistics Canada) (19), for Vienna (City of Vienna 
Information Center) (20), and Houston (United States Census Bureau) (21)).  The lead 
investigators of the PHL programs provided data on the number of hospitals, the proportion 
of hospitals with PCI facilities (PCI-hospital), and the annual incidence of STEMI within 
their jurisdictions.   
 In August 2008, we mailed a self-administered questionnaire (Appendix 2) to the 
lead investigators of the seven participating PHL programs.  The questionnaire collected 
data on pre-hospital services available, as well as information on the infrastructure of the 
PHL program and how the program worked (i.e., its processes).  Questionnaires were 
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completed in April 2009.  We re-contacted respondents in June 2010 to inquire about recent 
modifications to the PHL programs. 
. The investigators were also asked to report aggregate data since the initiation of 
the PHL program and also for the years 2005-08.   Outcomes data in these recent three 
years would be more clinically relevant than outcome data in the past decade since there 
were numerous recent innovations in the treatment of STEMI.   Due to confidentiality 
issues, we could not obtain individual patient data from the PHL programs surveyed. 
Results 
There was marked variation in the proportion of the population living in rural areas, 
and the mean population density in the areas surveyed (Table 1).  The mean population 
density varied from 16 persons/km2 in Nova Scotia to 4,189 persons/km2 in Vienna. The 
proportion of the population living in rural areas varied from 5% in Vienna to 45% in Nova 
Scotia.  Access to a PCI-hospital was limited in Nova Scotia, with only one PCI-hospital in 
this Canadian province (ratio of 900,000 persons/PCI-hospital, compared to 175,000 
persons/PCI hospital in Houston, United States).  
 In Vienna and France, 95% and 100% respectively of ambulances were staffed by 
physicians (Table 3). All the other PHL programs surveyed had paramedics and nurses 
(Sweden) able to provide advanced cardiac life support (i.e., advanced care paramedics 
(ACP)).  The PHL programs in London, Vienna, Houston, Edmonton, Sweden and Halifax 
had integrated regional networks to facilitate direct transfer of patients for primary 
PCI.(Table 4).  In Vienna and Sweden, all STEMI patients were transported directly to a 
PCI-hospital for primary PCI, except for patients who lived in very remote rural areas in 
Sweden.  In England/Wales, at the time of this survey, there was no formal transportation 
arrangement for primary PCI outside London.  In the greater London area, all STEMI 
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patients were transported directly for primary PCI. In Nova Scotia, direct transfer for 
primary PCI was only possible for patients with STEMI living in Halifax.   
Except for England/Wales where paramedics could independently initiate PHL, 
PHL could only be administered after transmission of pre-hospital ECG and authorization 
from responsible physicians in the other PHL programs (Table 4). In Houston, Nova-Scotia 
and Edmonton, PHL was administered by paramedics; in Sweden by ambulance nurses; 
and in France and Vienna, PHL was administered by physicians in the ambulances. 
Tables 5 and 6 describe the characteristics and outcomes of patients who received 
PHL.  Reinfarction was uncommon with cumulative incidences that ranged from 2.4% 
(France) to 5.8% (England/Wales). Less than 2% of PHL patients (≤0.6% in most 
programs) experienced in-hospital stroke.  The French PHL program had the lowest 
mortality at 2.7% in-hospital and 4.5% at 1-year while Sweden had the highest in-hospital 
mortality at 6.5% and 10.7% at 1-year.   
Discussion 
Although the efficacy and safety of PHL has been demonstrated in several 
randomized clinical trials (RCT)s (2-5), the generalizability of these results is limited by 
differences in characteristics of patients and systems of care in the “real-life” context. 
“Real-life” patients are often older and sicker with more co-morbidity than patients enrolled 
in RCTs (22). Because of their generally larger samples sizes and longer follow-up 
durations than RCTs (23-24), data from cohort studies such as those reported in this 
manuscript, may offer invaluable insights into the “real-life” effectiveness of PHL.  
There are several barriers to PHL implementation in North America (25).  First, the 
cost of a PHL program may be prohibitive for many pre-hospital agencies (25).  
Furthermore, emergency physicians may be reluctant to authorize PHL for patients whom 
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they have not yet evaluated, for fear of litigation. There may also be misperception that 
PHL is not necessary considering that 79% of Americans and 59% of Canadians live within 
an hour of a PCI-hospital (13,26) and therefore should be able to undergo primary PCI in a 
timely manner.  However, the above estimates were based on geographic distance without 
consideration of bad weather and traffic congestion.  Despite the large number of PCI-
hospitals and shorter distance to PCI-hospitals in Europe, PHL remains a valuable 
reperfusion strategy endorsed by the European Society of Cardiology (8-10).  
Pre-hospital ECG is an essential prerequisite for PHL, which is endorsed by the 
American Heart Association and American College of Cardiology (2).  However, only a 
minority of North American pre-hospital medical services can perform ECGs in 
ambulances (11,12).  Transmission problems might also prevent implementation of pre-
hospital ECG in many regions. Among the PHL programs surveyed, ECG interpretation in 
ambulances can either be automated (i.e., interpreted by a computer) or undertaken by 
paramedics or by nurses. Although ECG transmission could be helpful for patients with 
unclear diagnoses, well-trained paramedics and nurses could diagnose and treat most 
STEMI successfully without ECG transmission. 
The outcomes reported in this manuscript provide critical insights into the 
effectiveness and safety of PHL within several different contexts and time spans.  These 
results were similar to the outcomes reported by other American PHL programs (27).  
Denktas et al. reported similarly low incidences of major adverse outcomes (mortality of 
3.8%, stroke of 1.8% and reinfarction of 0.8%).  The higher in-hospital and one-year 
mortality in patients who received PHL in Sweden, relative to PHL in other jurisdictions 
may be partially explained by a 5-year difference in mean age.  Overall, the relatively low 
incidences of major adverse outcomes following PHL suggest that this reperfusion strategy 
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can be administered safely and effectively by health care professionals of diverse trainings 
and expertises.  
PHL should not be viewed as an alternate option, but rather as a complementary 
reperfusion strategy to primary PCI for patients with STEMI.  An ideal PHL program 
would incorporate formal protocols that identify patients who would benefit from direct 
transport for primary PCI where appropriate, and those who would benefit from early FL. It 
would need to assess who the patient is (i.e. patient characteristics), where the patient is (i.e. 
distance from a PCI hospital), what is available for treatment, and how soon the patient 
presents after onset of symptoms. In this way, tailored reperfusion therapy could be 
provided for each STEMI patient depending on their characteristics and circumstances.   
In addition to facilitating transfer, integrated regional networks of PCI-hospitals can 
be invaluable for continuing cardiac care following PHL.  After PHL, patients can be 
transferred to PCI-hospitals and then triaged for selective non-urgent PCI for patients with 
successful coronary flow restoration with PHL or rescue PCI for patients who did not have 
successful PHL.  By expediting coronary reperfusion, PHL can prevent undue time delays 
with the associated increased risks of mortality and irreversible myocardial damage.  In 
addition, PHL may reduce the economic burden of STEMI by decreasing the need for 
urgent PCI outside regular working hours.  
Limitations 
  First, comparison of morbidity and mortality data across PHL programs could not 
be undertaken due to the lack of individual patient data. Second, our description of 
infrastructures and processes of selected PHL programs relied on self-administered 
questionnaires completed by different administrators. Although we did query some 
inconsistencies and cross-check some data with other sources of information (28) and other 
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experts in reperfusion therapy, we did not systematically validate all responses provided by 
the investigators.  Third, our survey did not incorporate economic and quality assurance 
aspects (i.e., paying process of the fibrinolytic drugs, training and monitoring of outcomes, 
etc).  Finally, the outcome data were drawn from observational studies and therefore 
subject to all the biases inherent to this type of study such as selection, confounding and 
information bias.   In spite of these limitations, we believe that the outcome data on PHL as 
reported in this manuscript, provide valuable information and may serve as a benchmark for 
other programs of reperfusion therapy.  
Conclusion 
 PHL has been successfully deployed in a wide range of geographical contexts with 
varying population densities, access to PCI-hospitals and annual incidence of STEMI. PHL 
systems comprise a variety of processes that can be adapted to local contexts.  PHL can be 
safely delivered by health care professionals with different levels of training and expertise 
in a wide variety of settings. Even in areas with rapid access to primary PCI, PHL remains 
a valuable reperfusion strategy for patients with expected prolonged time delays from first 
medical contact to coronary flow restoration by primary PCI. 
 Combining PHL with formal protocols for direct transportation of patients to a 
PCI-hospital for primary PCI would allow tailored reperfusion therapy for patients with 
STEMI.  Insights from a variety of international settings may promote widespread use of 
PHL and increase timely coronary reperfusion worldwide.  
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Table 1.  Characteristics of countries, provinces and cities with pre-hospital 
fibrinolysis programs in 2010 
 
 Country Province City
 England/ 
Wales 
Sweden France 
 
Nova-
Scotia 
Canada 
Housto
Texas 
United 
States* 
Edmonton 
(Canada) 
Vienna 
Austria 
Total 
population 
(million) 
served by 
the PHL 
program 
54.5 9.0 61.0 0.9 2.1 1.2 1.7
Area (km2) 
served by 
PHL 
program 
151 174 441 370 551 500 55 491 1 499 9 532 414
Population 
density  
(mean no. 
persons/km2) 
360 21 112 16 1 400 126 4,589
Rural 
population  
(% of total 
population) 
20 15 17 45 NA 15 5
No. 
STEMI/year 
27 000 6 000 35 000 NA 211 780 1 200
No. 
STEMI/100,
000 
population 
50 66 55 NA 10 65 70
No. hospitals 
that provide 
STEMI care 
224 74 223 8 30 5 6
No. hospitals 
with PCI 
facility (% 
of hospitals 
that provide 
STEMI care) 
98 (44) 
 
29 (39) 
 
127 (57) 
 
1 (12.5) 22 (73) 2 (40) 6 (100)
Population 
per hospital 
with PCI 
facility 
556 122 
 
310 344 480 315 
 
900 000 175 000 600 000 316 666
PCI: Percutaneous Coronary Intervention 
STEMI: acute myocardial infarction with ST-segment elevation 
NA= Not available  
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Table 2. Interpretation and transmission of pre-hospital ECG in 2010 
 
 Country Province City 
 England 
and 
Wales 
Sweden France 
 
Nova-
Scotia 
Canada 
Houston
Texas 
United 
States 
Edmonto
nCanada 
Vienna 
Austria 
Year pre-
hospital 
ECG 
became 
available 
2000 1990 1990 2006 2005 2002 2000
% of 
ambulance 
personnel 
trained to 
interpret 
ECG 
 
100 100 100 100 100 32 100
Electronic 
transmission  
of  ECG, % 
of pre-
hospital 
ECG 
Not 
routinely 
done 
100 0 100 100 100 Pilot
Failed 
electronic 
transmission 
of pre-
hospital 
ECG  
NA ≤1% NA 10 20 2 NA
 ECG: Electrocardiogram 
 NA: Not applicable 
 STEMI:  ST-Segment Elevation Myocardial Infarction 
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Table 3.  Expertise of the professionals responsible for pre-hospital management of 
patients with STEMI in 2010 
 
 Country Province City 
 England 
and 
Wales 
Sweden France 
 
 
Nova-
Scotia 
Canada 
Houston
Texas 
United 
States 
Edmonton 
Alberta 
Canada 
Vienna 
Austria 
MD in the 
ambulances, 
% of 
ambulances 
0 0 100 0 0 0 95
% of 
ambulances 
with 
advanced 
care 
paramedics  
100 100 100 51 100 100 5
Responsible 
for 
telephonic 
guidance for 
STEMI 
management  
ER MD 
or CCU  
nurses 
ER or 
CCU 
MD 
NA ER MD ER MD ER MD and 
cardiologist 
ER MD and 
cardiologist 
Advanced care paramedics: paramedics who can provide advanced cardiac life support without supervision 
CCU:  Coronary Care Unit 
ER: Emergency room affiliated with the surveyed pre-hospital services 
MD:  Medical Doctor        
NA: Not applicable 
PCI: Percutaneous Coronary Intervention    
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Table 4.  Pre-hospital care of patients with ST-Segment Elevation Myocardial 
Infarction in 2010 
 Country Province City
 England 
and Wales 
Sweden France 
 
Nova 
Scotia 
Canada 
Houston
, Texas, 
United 
States 
Edmonton, 
Canada 
Vienna, 
Austria 
Routine 
transfer of 
patients 
for 
primary 
PCI, % of 
STEMI 
patients 
100 for 
London, no 
routine 
transfer for 
primary PCI 
outside 
London 
87 NA Only in 
Halifax 
85 60 100* 
 
Authorize 
PHL 
Paramedics ER MD MD in the 
ambulances 
MD 
affiliated 
with the 
pre-
hospital 
services
ER MD MD 
affiliated 
with the 
pre-
hospital 
services
MD in the 
ambulances 
Routine 
angiograp
hy after 
PHL, % of 
patients 
who 
received 
PHL 
75 50 85 100% in  
Halifax 
only 
100 90 90
MD:  Medical Doctor 
ER = Emergency room 
FL= Fibrinolytic Therapy 
NA = Not Available 
PHL= Pre-hospital Fibrinolysis 
TNK = Tenecteplase 
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Table 5. Characteristics of patients who received pre-hospital fibrinolytic therapy 
 England 
and 
Wales 
2003-8 
France 
2000 
 
France 
2005 
Edmonton 
2000-
2002 
Vienna 
2003-8 
Vienna 
2005-8 
Sweden 
1995- 
2008 
Sweden 
2005-8 
No. of 
patients 
12 888 
 
180 331 119 350 191 6,643 883
Mean age, 
years (SD) 
 
62.1 
(12) 
59.4 
(13) 
60.5 
(13) 
61.3 
(NA) 
58 
(12) 
57 
(12) 
66.4  
(11) 
66.7 
(11) 
 
Female, % 21.8 16.0 20.5 24.4 26.6 28.6 28.0 27.0
Mean 
systolic 
blood 
pressure, 
mmHg 
(SD)  
 
133  
(25) 
127 
(23) 
130 
(25) 
120 129 
(27) 
132 
(27) 
135.5 
(27.6) 
135.9 
(27.6). 
 
Prior 
myocardial 
infarction, 
% 
11 10 
 
9 17.1 12 12 17 
 
13
Prior PCI, 
% 
13 7 7 NA 5 5 5 6
Prior 
CABG, % 
2 2 2 NA 1 0.5 3 2
Prior CVA, 
%  
2 1 1 NA NA NA 4 5
PCI:  Percutaneous Coronary Intervention 
CABG:  Coronary Artery Bypass Surgery   
CVA:  Cerebro-Vascular Accident 
NA: Not Available 
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Table 6. Major adverse events in patients who received pre-hospital fibrinolytic 
therapy 
 
Jurisdiction England 
Wales 
2003-8 
France 
2000 
 
France 
2005 
Edmonton 
2000-
2002 
Vienna 
2003-8 
Vienna 
2005-8 
Sweden 
1995- 
2008 
Sweden 
2005-8 
Major bleed, %  0.9* NA 1.2 10.9 3.7 3.1 2.4 3.5
Reinfarction, % 5.2† 2.8 2.4 5.0 5.4 5.2 2.9 1.5
Stroke, % 0.5# 
 1.1 0.6 1.7
1.4 
 1.6 0.6 0.8
In-hospital 
mortality, % 3.3§ 3.3 2.7 3.4 6.5 4.7 6.5 5.7
One-year 
mortality, % 
   6.9|| 
 5.6 4.5 NA NA NA 10.9 10.4
*= Data available for 11 170 patients  
†= Reinfarction was ascertained only since 2005 
# = Data available for 11 310 patients 
§= Data available for 5 941 patients (2007-8) 
||= Data available for 5 721 patients (2007-8) 
NA = Not available 
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Chapter 6 
Manuscript 3 
6.1 Preamble 
 The extensive reviews of pre- and in-hospital reperfusion therapies (RT) in the first 
two manuscripts of this dissertation (66-67) will contribute to improved management of 
patients with acute myocardial infarction and ST-segment elevation (STEMI).  Although 
highly lethal, STEMI constitutes only a minority of the burdens of mortality and morbidity 
of acute coronary syndromes (ACS) (187).  The majority of patients with ACS have ACS 
without ST-segment elevation (NSTE-ACS) (187).  This condition occurs with sub-total 
occlusion of a coronary artery (187).  Patients with NSTE-ACS often have poorer long-
term survival than that of patients with STEMI due to more co-morbidity and less optimal 
use of evidence-based medical therapy (218).   
 Management of patients with ACS varies substantially from basic medication such 
as aspirin for low-risk patients, to urgent percutaneous coronary intervention (PCI) for 
high-risk patients (7,189). Inappropriate administration of potent medications or invasive 
intervention in low-risk patients is costly and exposes these patients to unnecessary side 
effects (7,189).  Conversely, high-risk patients with ACS might not receive life-saving 
procedures or medication if they are not identified as high-risk in a timely manner (7,187-
190). Therefore, early and accurate stratification of patients with ACS according to risk is 
the cornerstone of the optimal management of these patients (7,187-190).     
There are numerous prognostic tools available to assess ACS risk during 
hospitalization (219). However, there are no appropriate tools to assess risk during the pre-
hospital period.  To be widely applicable in the pre-hospital context and to avoid undue 
delays in providing optimal care to ACS patients, the ideal ACS risk score should be 
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simple, easy to memorize and “calculable” by health care providers without advanced 
medical training (i.e.,  primary care paramedics, ambulance technicians).  Its computation 
should not require a calculator or hand-held personal computer and it should not require 
lengthy questioning or examination of patients. In addition, the ideal risk score should be 
accurate for risk stratification in all types of ACS. The availability of pre-hospital recording 
and interpretation of electrocardiograms is highly variable and even non-existent in several 
Canadian jurisdictions (162). Therefore, a pre-hospital risk score should not require an 
electrocardiogram and should have similar prognostic value in all types of ACS patients.   
 The last manuscript of this thesis describes the development and validation of a risk 
score, the Canadian Acute Coronary Syndromes (C-ACS) index (204).  The prognostic 
value of the C-ACS index is examined in six large datasets of patients with ACS (204).  Its 
simplicity renders this risk score useful for pre-hospital management of patients with ACS.   
6.2. Methods 
6.2.1 Inclusion of datasets and patients with ACS   
The risk score was developed and validated using datasets of observational studies 
since risk score based on RCTs might have lower predictive value in “real-life” patients 
with ACS (220).  I identified observational studies of patients with ACS in the “Pubmed” 
database using the following keywords: “acute coronary syndromes”, “myocardial 
infarction”, and “unstable angina”.  To enable completion of the analysis within a 
reasonable time frame, I initially retained only observational studies of ACS patients in 
Canada.   I contacted the principal investigators of each study to solicit their collaboration 
either by providing their dataset, or by undertaking the required analyses with their 
datasets.  Subsequently, the FAST-MI principal investigator manifested interest in the risk 
score and volunteered to participate in this project (145).   
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Description of included datasets 
I had direct access to the AMI-QUEBEC (Acute Myocardial Infarction in Quebec) 
(182) and the CANADA ACS-1 (Acute Coronary Syndromes-1) datasets (7).  Direct access 
to the other datasets (i.e., CANADA ACS-2 (Acute Coronary Syndromes-2) (8), GRACE-
CANADA (Global Registry of Acute Coronary Syndromes in Canada) (186), the EFFECT-
1 (221) and the FAST-MI (FAST-MI French registry of Acute ST-elevation and non–ST-
elevation Myocardial Infarction) (145) was not possible due to local institutional 
regulations. The biostatisticians affiliated with these research groups completed the 
analyses of these datasets.  
Inclusion of patients with ACS - All datasets retained included only adult patients 
(i.e., ≥18 years old) who survived long enough for presentation at the hospital.  We did not 
include patients who died at home or during ambulance transportation.  We also excluded 
patients without a final diagnosis of an ACS condition (i.e., unstable angina, STEMI, non-
STEMI).  
6.2.2 Definitions of endpoints and ascertainment of survival status 
Definitions of endpoints  
The primary endpoints of interest were short- and long-term all-cause mortality.  I 
selected all-cause mortality as the primary endpoint since this is the most objective and 
reliable endpoint (82).  Its ascertainment does not depend on subjective classification of 
cause of death, which may be prone to ascertainment bias (82).  Short-term mortality was 
defined as all-cause mortality that occurred up to 30 days after the index ACS event.  Long-
term mortality was defined as all-cause mortality that occurred at least 30 days after the 
index ACS event. 
Determination of survival status  
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Local data abstractors determined the in-hospital survival status of patients in the 
studies included in this analysis.  One-year survival was ascertained by contacting patients 
enrolled in the CANADA ACS-1-2 study (telephone contact with patients and/or families), 
and through linkage with health care databases in the EFFECT-1 (221), and FAST-MI 
(145).  Five-year survival was ascertained through linkage with provincial and institutional 
health care administrative databases for the AMI-QUEBEC study (182).  Data on one-year 
survival were not available for the GRACE-CANADA study (186). 
6.2.3. Development of the risk score 
Selection of components for the risk score 
 Since the purpose of this project was to develop a risk score that can be applied in a 
pre-hospital context, I retained only those clinical variables that are generally available at 
the time of the first medical contact.  I excluded variables requiring electrocardiographic 
(ECG) data. Variables retained for consideration in the risk score were age, female gender, 
history of diabetes mellitus, prior myocardial infarction, prior coronary intervention, prior 
stroke, systolic blood pressure (SBP), heart rate (HR) and Killip class (i.e., a class of 
severity of myocardial infarction categorized by the presence or absence of heart failure. 
Killip class is an ordinal scale with values ranging from 1-4, with 1 indicating absence of 
heart failure and 4 indicating severe heart failure).  
Since I had full access to the data, I used the AMI-QUEBEC (182) and the CANADA 
ACS-1 (7) datasets to develop the risk score.  I completed univariate logistic regression 
analyses to assess the association between each indicator with in-hospital mortality.  I 
entered indicators with p-values ≤0.10 univariately into a multivariate logistic regression 
model, and used backward selection to identify variables with independent associations 
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with in-hospital mortality.  Indicators retained in the final model included age, systolic 
blood pressure (SBP), heart rate (HR) and Killip class at initial presentation.   
To ensure simplicity, I transformed the indicators in the risk score into categorical 
variables.  I tested alternate combinations of categorical variables (≥65 years, ≥70 years, 
≥75 years), SBP (<100 mmHg, <120 mmHg), HR (≥100/minute, ≥120/minute), and (Killip 
≥1, ≥2, ≥3).  For each combination, I calculated the area under the receiver operating 
characteristic curve.   A receiver operating curve is the plot of sensitivity versus 1-
specificity (i.e., a plot of proportion of true positives versus false positives for all values of 
the risk score).   
The area under this curve, also called the c-statistic or the c-index, is the probability 
that a patient who dies has a risk score value greater than that of a patient who survives 
(222-225).  C-statistics have values ranging from 0.5 (no discrimination) to 1 (perfect 
discrimination) (222-223).  The final cut-off values were selected based on the combination 
of indicators and cut-offs with the highest c-statistic.  The final risk score is a composite of 
four categorical variables: age ≥75, SBP <100 mm Hg, HR >100/minute, and Killip class 
>1.  It is continuous with values ranging from 0 to 4, with each indicator assigned a score 
of 0 or 1 depending on its presence or absence.   
Potential collinearity of the components of the risk score 
  In a correlation matrix, there was no statistically significant correlation between the 
indicators retained in the C-ACS, suggesting absence of significant collinearity in the 
model. 
Discriminant and calibration functions  
I evaluated the discriminant function (i.e., ability of the risk score to correctly classify 
subjects with and without risk) using a receiver operating curve (222). C-statistics of 
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approximately 0.75 or greater are considered to have superior discrimination value (222-
223).   
The calibration function of a risk score is the estimated predictive value of the risk 
score (223-225).  An assessment of calibration refers to the direct comparison of the 
observed and predicted mortality (223-225).  I evaluated calibration using the Hosmer-
Lemeshow goodness of-fit test.  This test compares the observed and predicted proportions 
within each decile of estimated risk (223). A p-value ≥0.10 indicates no statistically 
significant difference between observed and expected values (i.e., a good fit of the model) 
(223). 
Sensitivity analyses 
In patient with impaired heart function, the heart generally compensates by increasing 
its rate to maintain adequate blood flow.  Tachycardia (HR >100 per minute) is frequently 
the result of depressed heart function.  However, injury to the electrical system of the heart 
of AMI patients may induce very slow HR (HR <50 per minute) or very fast HR (HR>150 
per minute) (1).  These patients may have HR <50 per minute or >150 per minute, 
regardless of heart function. The proposed risk score may be less accurate in predicting 
mortality in these patients.   
Analyses of receiver operating curve and goodness-of-fit tests were undertaken 
initially including all patients.  I then undertook sensitivity analyses excluding patients with 
an initial HR <50 per minute and >150 per minute in all datasets.  
Subgroup analyses 
I determined the c-stastistics of the C-ACS in several subgroups of patients in the 
AMI-QUEBEC dataset for both short- and long-term mortalities in Appendix 5. The index 
has good discriminant properties in all of the subgroups studied (i.e. ≥0.70) except in 
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patients ≥65 years old where its c-statistics are 0.69 for both short- and long-term 
mortalities.  These results suggested that the C-ACS should have good predictive values in 
identifying the majority of patients at increased risk for short- and long-term death. 
Missing data 
I first evaluated discriminant function and model fit in a dataset including only 
patients with complete data on age, Killip class, blood pressure and heart rate. I then reran 
the analyses imputing values for missing indicators using three different methods (means, 
estimates of maximum likelihood and regression). 
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Background: There are several prognostic risk scores for acute coronary syndromes 
(ACS), but none are appropriate for use at the time of first medical contact with ACS 
patients.  The objective of this study was to develop a simple risk score that can be used for 
pre-hospital risk stratification of ACS patients. 
Methods: We developed the risk score using data from the AMI-QUEBEC and Canada 
ACS-1 registries, and then validated it in four large datasets of ACS patients (the Canada 
ACS-2, Canada -GRACE, EFFECT-1 and FAST-MI registries). The “C-ACS risk score” 
ranged from 0-4, with 1 point each assigned for the presence of age ≥75 years, Killip >1, 
systolic blood pressure <100 mmHg and heart rate <100 beats/minute. The primary 
endpoints used to validate the score were short- (in-hospital or 30-day) and long-term (1 or 
5-year) all-cause mortality.     
Results: The C-ACS had good predictive validity for short and long-term mortality of 
patients with STEMI and NSTE-ACS.  The negative predictive value of a C-ACS score ≥1 
is excellent (i.e. a C-ACS score of 0 correctly identifies ≥98% short-term survivors and 
≥91% long-term survivors). 
Conclusion: The C-ACS risk score permits early identification of high risk ACS patients.  
Since the score is simple, and easy to memorize and calculate, it can be rapidly applied by 
health care professionals without advanced medical training.   
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Condensed Abstract 
            We developed a risk score for early risk prognostication of patients with acute 
coronary syndromes.  The C-ACS risk score is an ordinal scale with 1 point assigned to 
each of age ≥75 years, Killip >1, systolic blood pressure <100 mmHg and heart rate <100 
beats per minute. The C-ACS risk score has good predictive validity with c-statistic values 
≥0.75 for short- and long-term mortality in six large cohorts of patients with acute coronary 
syndromes.  Since this risk score is simple and easy to memorize and calculate, it can be 
used by health care professionals without advanced medical training.   
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C-ACS:  A New Risk Score for Early Prognostication in Acute Coronary Syndromes 
 
Background 
Patients with acute coronary syndromes (ACS) have marked variation in mortality 
risk (1-2). High-risk patients derive survival benefit with administration of potent 
medications and prompt coronary revascularization (1-2).  However, inappropriate use of 
these treatments in low-risk patients exposes them unnecessarily to possible adverse side 
effects (1-2).     
Several ACS prognostic risk scores exist, but none is appropriate for early risk 
stratification at the time of the first medical contact between the health care provider and 
the patient, before the results of electrocardiogram (ECG) or cardiac biomarkers are 
available.  To be easily applicable at the time of first medical contact, an ACS risk score 
must be simple and easy to memorize and calculate by health care providers without 
advanced medical training. The objective of this study was to develop and validate a 
simple, accurate risk score that can be used for early risk stratification of ACS patients at 
the time of the first medical contact. 
Methods  
Inclusion of datasets of ACS patients  
          We used the AMI-QUEBEC (Acute Myocardial Infarction in Quebec) (3) and the 
Canada ACS-1 registries (4)   to develop the risk score. We validated the risk score in four 
datasets of ACS patients (i.e., the Canada ACS- 2 registry (5), Canada GRACE (Global 
Registry of Acute Coronary Events (Canadian subgroup) (6), EFFECT-1 (Enhanced 
Feedback for Effective Cardiac Treatment), (7) and the FAST-MI (French registry of Acute 
ST-elevation and non–ST-elevation Myocardial Infarction) (8). All six datasets included 
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adult patients only (i.e., >18 years old) who survived long enough for hospital admission.  
Patients who died at home or during ambulance transportation were excluded. 
          The AMI-QUEBEC Study was a retrospective chart review of all patients with 
STEMI admitted to 17 Quebec hospitals in 2003 (3).  The EFFECT-1 study randomly 
sampled AMI patients in the Ontario hospital administrative database (7).  The Canada-
GRACE study enrolled ten consecutive patients with ACS monthly during a 6-month 
period at participating hospitals (8).  Enrolment of patients was consecutive in all other 
studies.  Four studies (i.e., the Canada ACS-1 and-2, Canada-GRACE, and FAST-MI) 
collected data prospectively (4-6, 8). Written informed patient consent was required in three 
studies (i.e., the Canada ACS-1 and -2 and FAST-MI) (4-5, 8).  For patients with more than 
one ACS admission during the study period, only the first ACS admission was retained for 
analysis in all studies.  
Definitions of endpoints  
Endpoints - The primary endpoints were short and long-term all-cause mortality.    Short-
term mortality was defined as all-cause death that occurred during hospitalization for the 
index ACS event (AMI-QUEBEC, Canada ACS-1, ACS-2, Canada-GRACE and EFFECT-
1) (3-7) or 30-day mortality (FAST-MI) (8).  Long-term mortality was defined as all-cause 
mortality at one year (ACS-1 and 2, EFFECT-1) (4-5, 7), (FAST-MI) (8) and 5-year 
following the index ACS event (AMI-QUEBEC) (3). 
Determination of survival status - In-hospital survival status was determined in chart 
reviews.  Long-term survival was ascertained in telephone contacts with patients and/or 
their families in the Canada ACS-1 and 2 registries (4-5), or through linkage with the 
provincial health care databases in the EFFECT-1 (7) and the AMI-QUEBEC studies.  In 
the FAST-MI study, survival data were obtained by contacting patients, families and 
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attending physicians; missing survival data were collected through linkage with 
administrative datasets (8).  Data on one-year survival were not available in the Canada-
GRACE study.   
Development of risk score 
Selection of variables 
We retained only clinical variables as possible components of the risk score which 
can be easily obtained in the pre-hospital setting or emergency room. Categorical indicators 
considered for inclusion in the score included: female sex, history of diabetes mellitus, 
prior myocardial infarction, prior coronary intervention (i.e., coronary artery bypass surgery 
or percutaneous coronary intervention (PCI)) and prior stroke.  Continuous indicators 
included age, initial systolic blood pressure (SBP), and initial heart rate (HR).  Initial Killip 
class was considered as ordinal.  
Statistical analyses 
 
We used the AMI-QUEBEC and the CANADA-ACS-1 datasets to develop the risk 
score. Univariate logistic regression models were used to assess the association between 
each indicator and in-hospital mortality. We then entered indicators with p-values ≤0.10 
into a multivariate logistic regression model with stepwise selection to identify indicators 
that were independently associated with in-hospital mortality.  We tested the fit of the final 
model with the Hosmer-Lemeshow Goodness of Fit test. 
A risk score with categorical rather than continuous variables would be more easily 
remembered and applied by clinicians. Therefore, we tested alternate combinations of 
categorical variables (≥65 years, ≥70 years, ≥75 years), SBP (<100 mmHg, <120 mmHg), 
HR (≥100/minute, ≥120/minute), and (Killip ≥1, ≥2, ≥3). For each combination, we 
calculated the c-statistic (i.e., area under the receiver operating characteristic (ROC) curve).   
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C-statistic values of ≥0.75 are generally considered to have good discriminant properties 
(9). The final risk score was an ordinal scale ranging from 0-4, with 1 point assigned for 
age ≥75 years, Killip >1, SBP <100 mmHg and HR >100 beats/minute.  We named it the 
C-ACS risk score (C for Canada, and ACS for Acute Coronary Syndrome).  
We compared the predictive value of the C-ACS risk score with other existing risk 
scores including GRACE (10), EMMACE (Evaluation of the Methods and Management of 
Acute Coronary Events) (11), TIMI risk score (Thrombolysis in Myocardial Infarction) 
(12), TIMI risk index (13), PAMI (Primary Angioplasty in Myocardial Infarction) (14) in 
the AMI-QUEBEC and CANADA ACS-1(15).  We computed the predictive values of the 
C-ACS risk score for patients with STEMI and ACS without ST-segment elevation (NSTE-
ACS) in the other datasets (Canada ACS-2, Canada-GRACE, EFFECT-1 and FAST-MI).  
We examined the positive and negative predictive values of each of the four values of the 
C-ACS risk score in all six datasets.   
    
Data from EFFECT-1 were analyzed using SAS version 9.1.  Data from all other 
studies were analyzed using SPSS version 18. Comparison of c-statistics across risk scores 
was undertaken with MEDCALC version 12.1.1.   
Results 
Characteristics of the registries are summarized in Table 1.  Missing data prevented 
computation of the C-ACS risk score in only  a minority of patients (4.1% in AMI-
QUEBEC, 8.0% in ACS-1, 4.2% in ACS-2, 8.2% in CANADA-GRACE 1.6% in EFFECT-
1 and 0.8% in FAST-MI).   
We described selected characteristics and mortality in patients in each registry in 
Table 2.  There were a total of 33,162 patients (30% female).  Most had ACS without ST-
segment elevation (NSTE-ACS).  Patients enrolled in the Canada ACS-1 and-2 and 
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Canada-GRACE registries had the lowest mortality (<4% during hospitalization; <9% at 1-
year).  The EFFECT-1 patients had the highest mortality (10% in-hospital; and 17% at 1-
year for STEMI and 22% for NSTE-ACS).   
Tables 3 and 4 compare the c-statistic of the C-ACS risk score to that of other risk 
scores in the AMI-QUEBEC and CANADA ACS-1 cohorts.  In the AMI-QUEBEC study, 
which included only STEMI patients, the C-ACS c-statistic for long-term mortality was 
comparable to those of more complex risk scores (GRACE, EMMACE, PAMI, TIMI risk 
score and TTIMI risk index).   In the CANADA ACS-1 cohort, which enrolled STEMI and 
NSTE-ACS patients, the c-statistic of the C-ACS risk score was adequate (≥ 0.73) but 
slightly inferior to other risk scores in predicting short- and long-term mortality. Table 5 
reports the c-statistic of the C-ACS risk score in both types of ACS (with and without ST-
segment elevation) in all six datasets (Table 5).  The c-statistic of the C-ACS risk score was 
fair with values ≥0.72 in all registries. 
We examined the positive and negative predictive values of each of the four values of 
the C-ACS risk score in the six datasets. The negative predictive value (NPV) of a C-ACS 
score ≥1 was excellent at ≥98% for in-hospital mortality and ≥91% for long-term mortality 
(a C-ACS score of 0 correctly identified ≥98% of in-hospital survivors and ≥91% of long-
term survivors).   
Discussion 
Clinical relevance of a risk score for early risk stratification of ACS patients 
The relevance of creating another risk score when there are already several risk scores 
available for ACS prognostication may be questioned (10-14, 17-28).  Most existing risk 
scores require clinical and biological data that only become available after hospitalization 
and testing. Only the TIMI risk index (13), AODE (Averaged One- Dependence 
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Estimators) (17) and EMMACE (11) can be applied at the time of the first medical contact.  
However, these risk scores require computation by calculators or hand-held computers.  
Furthermore, the TIMI risk index has not been validated in patients with heart rates ≥150 or 
<50 per minute (13).  In contrast to the TIMI risk index and the EMMACE risk score, the 
C-ACS risk score does not require ECG, blood sampling or a calculator.  C-ACS can be 
easily memorized and calculated and it is applicable in all types of ACS patients.  Since 
ECG acquisition and/or interpretation is difficult or impossible in many North-American 
pre-hospital settings (29), the lack of requirement for ECG  makes the C-ACS risk more 
easily applicable than other risk scores in North America.  
High-risk NSTE-ACS patients who require urgent PCI may benefit from direct 
transfer to hospitals with on-site PCI facilities. However, routine re-direction of NSTE-
ACS patients to hospitals with on-site PCI facilities would divert limited resources (i.e., 
mobilization of ambulances for prolonged periods of time) without benefit to most NSTE-
ACS patients.  The excellent negative predictive value (≥0.95) and good sensitivity (≥0.82) 
of a C-ACS score ≥1, suggests that a C-ACS score of 0 is useful in the early identification 
of low-risk NSTE-ACS patients who do not need urgent PCI and can be managed 
conservatively initially. In-hospital management of these low-risk patients may be 
undertaken later after applying more complex risk scores.  Patients with a C-ACS score ≥3 
should be managed more aggressively with rapid transport to a hospital with a PCI facility, 
since these patients have a high mortality risk. 
Validity of the C-ACS risk score 
 Risk scores can be validated either internally or externally.  External validation is 
preferred since internal validation is prone to over-optimism (30-31).  The external 
validation of the C-ACS risk score in several large populations with STEMI and NSTE-
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ACS ), across different time periods (EFFECT- 1 was conducted in 1999, and the other 
studies were conducted during 2003-2005), different geographical locations and systems of 
care (i.e., several Canadian provinces, and France) and diverse therapeutic strategies (i.e., 
more frequent invasive interventions in the AMI-QUEBEC and FAST-MI patients versus 
more conservative management in EFFECT-1, Canada ACS-2, and Canada GRACE 
patients) supports its predictive value and applicability to  ACS patients in diverse contexts. 
Furthermore, the good predictive value of the C-ACS risk score in the various registries 
suggests that it may be more valid in real-life patients, in contrast to other risk scores that 
were validated in randomized clinical trials (32). 
Potential uptake of the C-ACS risk score 
Despite their superiority to physician assessment (32-33), ACS risk scores remain 
under-used in clinical practice (34-35).  This may in part contribute to the “treatment 
paradox” whereby high-risk ACS patients are often undertreated compared to lower-risk 
patients (36-37).  The reluctance of physicians to apply a formal risk score in the 
management of ACS patients might be due to the complexity of available risk scores, the 
requirement for a calculator or computer, as well as limited availability of data for several 
clinical variables (34-35).  The C-ACS score may promote more optimal early management 
of ACS patients because it is a simple ordinal scale with indicators that can be easily 
obtained at the first medical contact. 
Limitations 
Study limitations include use of a categorical rather than a continuous scoring system, 
which may decrease the precision of the C-ACS score.  However, a categorical system is 
preferable in emergency situations due to its simplicity.  Second, we did not assess the 
accuracy and reliability of the indicators that comprise the C-ACS risk score.  In particular, 
133 
 
133 
 
the Killip classification is subjective and its accuracy might vary depending on the 
expertise of the observer.  Nevertheless Killip class ≥1 requires only simple indicators such 
as the presence of pulmonary rales and normal blood pressure.  These simple indicators can 
be evaluated by most health care professionals without advanced medical training. Third, 
due to its ordinal scale with only four possible values, we could not assess the calibration of 
the C-ACS score.  However, in agreement with Lee et al. (33) we believe that the 
discriminant function of a risk score should be given priority over its calibration.  
Depending on the case-mix of patients, all risk scores need to be re-calibrated for each 
population of interest.  Finally, the risk score was developed and validated in patients who 
survived to presentation at the hospital.  The applicability and accuracy of the C-ACS risk 
score for patients who die prior to hospital presentation remain to be determined.  
Conclusion 
The new C-ACS risk score has good predictive validity for short- and long-term 
mortality in several ACS populations.  It permits rapid identification of high risk ACS 
patients, before biological markers can be obtained. Since this risk score is simple and easy 
to memorize and calculate, it can be rapidly applied by health care professionals without 
advanced medical training.  Prompt early stratification of ACS patients will facilitate  
management tailored to individual patient risk profiles.  C-ACS risk score could have a 
large impact on early ACS care.    
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Table 1. Characteristics of the datasets used to develop or validate the C-ACS risk 
score  
 
 AMI-
QUEBEC 
Canada 
ACS-1 
Canada 
ACS-2 
Canada-
GRACE 
EFFECT-1 FAST-MI 
Sample 
size 
 
1 554 
 
4 627 
 
1 956 
 
10 195 
 
11 159 
 
3 670 
 
Sampling 
method 
 
Consecutive First 10 
consecutive 
patients 
monthly 
 
First 10 
consecutive 
patients 
monthly 
 
First 10 
consecutive 
patients 
monthly 
 
 
Random 
selection 
Consecutive 
patients 
hospitalized 
during one 
month 
 
Enrolment 
period  
 
2003 
 
1999-2001 
 
2002-3 
 
2004-2006 
 
1999-2001 
 
October 
2005 
 
 
Data 
collection 
 
Retrospective 
 
Prospective 
 
Prospective 
 
Prospective 
 
Retrospective 
 
Prospective 
 
Number of 
hospitals 
(Location) 
17 
(Quebec 
Canada) 
51 
(Canada) 
 
51 
(Canada) 
 
 
55 
(Canada) 
103 
(Ontario 
Canada) 
 
223 
(France) 
 
Type of 
ACS 
 
STEMI 
 
STEMI 
NSTE-ACS 
 
NSTE-ACS 
 
STEMI 
NSTE-ACS 
 
STEMI 
NSTE-ACS 
 
STEMI 
NSTE-ACS 
 
Patient 
consent 
required 
 
No Yes 
 
Yes 
 
Yes at some 
hospitals 
No 
 
Yes 
 
Survival 
data  
available 
 
In-hospital 
Five-year 
In-hospital 
One-year 
In-hospital 
One-year 
In-hospital 
Six-month 
 
In-hospital 
One-year 
 
In-hospital 
One -year 
 
ACS: Acute Coronary Syndromes 
AMI-QUEBEC:  Acute myocardial infarction in Quebec 
EFFECT-1: Enhanced Feedback for Effective Cardiac Treatment 
Canada-GRACE: Global registry of Acute Coronary Events (Canadian subgroup)  
NSTE-ACS: Acute Coronary Syndromes without ST-segment elevation 
STEMI:  ST-segment Elevation Myocardial Infarction 
FAST-MI:  French registry of Acute ST-elevation and non–ST-elevation Myocardial Infarction 
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Table 2. Clinical characteristics and mortality of patients enrolled in ACS datasets used to 
develop or validate the C-ACS risk score. 
 
  
AMI-
QUEBEC 
 
 
Canada 
ACS-1 
 
 
CanadaACS-
2 
 
 
Canada-
GRACE 
 
 
EFFECT-
1 
 
 
FAST-
MI 
 
Age, mean (SD) 62 (14) 65 (12) 66 (13) 67 (13) 67 (14) 67 (14) 
Age 75 years, % 19.3 25.3 27.5 31.2 34.9 34.6 
Female, % 27.9 31.4 32.9 34.1 35.7 31.5 
STEMI, % 100 36.8 0 27.5 49.3 51.0 
Diabetes mellitus, % 14.5 25.1 27.2 27.2 25.5 35.9 
Prior PCI, % 12.2 14.1 21.5 17.3 3.2 14.1 
Prior CABG, % 3.9 12.5 14.5 12.3 6.5 5.7 
Killip >1, % 17.5 17.3 16.0 16.2 26.6 24.0 
Initial SBP, mean, (SD) 138(32) 148 
(29) 
149 (30) 145 
(29) 
146 (33) 140 
(29) 
Initial HR, mean, (SD) 77(21) 76 (21) 79 (20.4) 82 (22) 84 (25) 80 (20) 
Initial SBP <100 mmHg, 
% 
10.8 3.0 2.8 4.8 6.3 6.0 
Initial HR >100/min, % 14.5 11.2 12.5 15.9 21.0 13.3 
 
Short-term mortality (%) 
STEMI 6.2 
 
3.9 NA 3.4 
 
9.9 
 
7.7 
at 30-
day 
NSTE-ACS NA 1.6 1.8 2.6 9.7 
 
5.6 
at 30-
day 
 
Long-term mortality (%) 
STEMI 11.8 at 5-
year 
11.9 NA NA 17.1 11.9 
NSTE-ACS NA 8.3 6.9 NA 21.8 16.0 
 
ACS: Acute Coronary Syndromes 
AMI:  Acute Myocardial Infarction, 
AMI-QUEBEC:  Acute myocardial infarction in Quebec 
CABG:  Coronary Artery Bypass Surgery 
Canada- GRACE: Global registry of Acute Coronary Events (Canadian subgroup), 
EFFECT-1: Enhanced Feedback for Effective Cardiac Treatment 
FAST-MI:  French registry of Acute ST-elevation and non–ST-elevation Myocardial Infarction 
HR:  Heart Rate 
NA:  Not available, 
NSTE-ACS:  Acute Coronary Syndromes without ST- segment elevation, 
PCI:  Percutaneous Coronary Intervention 
SBP:  Systolic Blood Pressure 
SD: Standard deviation 
STEMI:  ST-segment Elevation Myocardial Infarction. 
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Table 3. Comparison of the c-statistic for short-term mortality of the C-ACS risk 
scores and other available ACS risk scores in the development datasets 
 
Risk Score AMI-QUEBEC CANADA ACS-1  
C-statistic 
(95% CI) 
p-values* C-statistic  
(95% CI) 
p-values*  
C-ACS 0.73 ( 0.72-0.75) Not 
Applicable 
0.75 
(0.74 to 0.77) 
Not 
Applicable 
 
EMMACE 0.76 (0.75-0.77) 0.03 0.81(0.80 to 0.82) 
 
0.009 
GRACE 0.78 (0.77-0.79) <0.001 0.82(0.81 to 0.83) 
 
0.006 
PAMI 0.77 (0.76- 0.79) <0.001 0.77 (0.76-0.78) 0.20 
TIMI Index 0.77 (0.76-0.78) 0.04 0.80 
(0.79 to 0.81) 
0.04 
TIMI Risk 
Score 
0.77 (0.75-0.79) 0.80 NA NA 
*:  Comparison of the c-statistic of the risk score with the C-ACS by DeLong et al.’s method 
ACS:  Acute Coronary Syndromes 
C-ACS:  Canada Acute Myocardial Infarction 
CI:  Confidence Intervals 
EMMACE:  Evaluation of the Methods and Management of Acute Coronary Events 
GRACE:  Global Registry of Acute Coronary Events 
TIMI:  Thrombolysis in Myocardial Infarction 
PAMI:  Primary Angioplasty in Myocardial Infarction 
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Table 5. C-statistics of the C-ACS score for prediction of mortality of patients with 
ACS in several datasets 
 
Short-term mortality 
  
In-hospital 
AMI-
QUEBEC 
 (95% CI) 
 
 
In-hospital 
Canada-
ACS-1 
 (95% CI) 
 
In-hospital 
Canada-
ACS-2 
 (95% CI) 
 
In-hospital 
Canada-
GRACE 
 (95% CI) 
 
 
In-hospital 
EFFECT-1 
 (95% CI) 
 
Thirty-day 
FAST-MI 
 (95% CI) 
 
STEMI 
 
 
0.78  
(0.74-0.83) 
 
0.74 
 (0.68-0.81) 
 
 
NA 
 
 
0.78  
(0.85-0.82) 
 
0.79  
(0.78-0.81) 
 
0.76  
(0.72-0.80) 
 
NSTE-
ACS 
 
NA 
 
0.75  
(0.68-0.82) 
 
0.74  
(0.69-0.80) 
 
0.79  
(0.76-0.82) 
 
0.79  
(0.77-0.80) 
 
0.73  
(0.68-0.78) 
 
 
Long-term mortality 
 
 Five-year 
AMI-
QUEBEC 
 (95% CI) 
One-year 
Canada 
ACS-1 
 (95% CI)
One-year 
Canada 
ACS-2 
 (95% CI)
One-year 
Canada-
GRACE 
 (95% CI)
One-year 
EFFECT-1 
 (95% CI) 
One-year 
FAST-MI 
 (95% CI) 
 
STEMI 
 
0.76  
(0.72-0.81) 
 
 
0.72  
(0.68-0.76) 
 
 
NA 
 
 
NA 
 
0.79  
(0.77-0.80) 
 
0.78  
(0.74-0.81) 
 
NSTE-
ACS 
 
NA 
 
0.74  
(0.71-0.78) 
 
0.74  
(0.71-0.77) 
 
 
NA 
 
0.77  
(0.76-0.79) 
 
0.73  
(0.70-0.76) 
ACS: Acute Coronary Syndromes 
AMI-QUEBEC:  Acute myocardial infarction in Quebec 
Canada-GRACE : Global registry of Acute Coronary Events (Subgroup of enrolled patients from Canada) 
CI:  Confidence Intervals 
EFFECT-1: Enhanced Feedback for Effective Cardiac Treatment 
NA: Not Applicable 
NSTE-ACS:  Non-ST-segment elevation Acute Coronary Syndromes 
STEMI:  ST-Segment Elevation Myocardial Infarct 
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Chapter   7 
Discussion 
 In this chapter, I re-state the rationale for this thesis and summarize the results of 
each manuscript. The strengths and limitations of each manuscript, as well as the 
contribution of this work to the literature of acute coronary syndromes (ACS) are 
delineated.  Finally, I discuss future research directions and the impact of the findings of 
this doctoral dissertation on the organization of health care in Quebec. 
7.1 Rationale for the three manuscripts in this doctoral dissertation 
 ACS causes a large number of cardiovascular (CVD) deaths worldwide and 
generates enormous direct and indirect healthcare costs (10-11).  Myocardial infarction 
with ST-segment elevation (STEMI) accounts for a large proportion of the ACS burden 
(10-11).  Several recent innovations, such as primary percutaneous coronary intervention 
(PCI) and pre-hospital administration of fibrinolytic therapy (FL), improve survival in 
patients with STEMI in randomized controlled trials (RCT)s.  However, numerous 
questions remain about the feasibility, effectiveness, and safety of these treatments in less 
selected “real-life” patients, outside the rigorously controlled context of RCTs (38,194-
198).  Systematic reviews including recent RCTs using pre-hospital administration of FL 
(i.e., PHL) and associated interventions/medications (stents, novel medications) may 
provide a more accurate and contemporary comparison of primary PCI and FL.  
Furthermore, inclusion of data from observational studies would provide additional insight 
into safety and effectiveness of these two RT strategies in “real-life” patients.   
 Despite its proven superiority in mortality reduction compared to in-hospital 
administration of FL, PHL remains under-used outside Europe.  Understanding of the 
infrastructure and processes required for safe and effective PHL may assist policy-makers 
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in implementation of this RT strategy in North America.  Outcome data of patients who 
received PHL by experienced emergency medical system (EMS) personnel can serve as 
benchmark for other EMS providers.  
Optimal ACS management includes accurate and early risk stratification of ACS 
patients (7,187-190). However, despite superior discriminant validity compared to 
subjective physician evaluation, currently available risk scores remain infrequently used in 
the prognostication of ACS patients (191-192).  Suboptimal use of these risk score is likely 
due to the requirement for clinical data which may not be easily available, as well as for 
complex calculation.  Considering the widespread increased use of early PCI in patients 
with ACS (73,176-186), an accurate and user-friendly risk score may be of great utility in 
pre-hospital risk stratification of patients with ACS, so that these patients can be 
transported to the most appropriate hospital.  
7.2 Summary of the results of this doctoral dissertation 
 Overall, the three manuscripts in this thesis shed insight into critical knowledge 
gaps in the management of patients with ACS.   Although the efficacy and safety of 
primary PCI have been well demonstrated in several RCTs and meta-analyses of RCTs, its 
benefit in terms of reduction in mortality and morbidity in “real-life” patients with STEMI 
remain unclear (81).  Our meta-analysis of observational studies supports the superiority of 
primary PCI in reducing short-term (<6-weeks) mortality and stroke compared to FL in 
“real-life” patients with STEMI (66).   However, there was no conclusive evidence for a 
difference in long-term mortality and re-infarction between primary PCI and FL in the 
observational studies reviewed (66).  In the second manuscript, I showed that PHL can be 
safely administered in diverse international systems of care by health care providers with 
different levels of expertise (67).  Finally, I developed a simple risk score that can be easily 
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used by health care providers at the time of the first contact with ACS patients (204).  The 
validation of the C-ACS risk score in several large datasets of patients with different types 
of ACS and within diverse systems of care suggests excellent internal and external validity 
of this risk score (204).    
7.3 Limitations 
In this section, I discuss the limitations specific to each manuscript. 
7.3.1 Bayesian meta-analyses comparing primary PCI versus FL in RCTs and 
observational studies 
The main limitation of these meta-analyses is the potential for publication bias 
inherent in all meta-analyses.  It is well known that researchers and editors tend not to 
publish studies with negative results (i.e. when there is no detectable difference between 
the two treatment arms) (89).  Nevertheless, the lack of asymmetry in our funnel plots 
suggests that there was no omission of major negative studies (112). Another limitation of 
these meta-analyses is the inability to compare primary PCI with PHL, since PHL was 
administered in only three RCTs (12,13,15). Third, exclusion of studies not published as 
full manuscripts (i.e., presented as conference proceedings or in abstracts) might have 
affected the estimate of treatment effect.  However this exclusion was justified by the 
need for detailed quality evaluation for bias detection.   
7.3.2 International perspectives on pre-hospital FL 
Limitations of this manuscript include the lack of individual patient data, which 
prevented direct comparison of outcomes between the PHL programs surveyed (67).  
Furthermore, the results of this manuscript are based primarily on self-administered 
questionnaires completed by the administrators of participating PHL programs (67). 
Although I queried inconsistencies in the data, and cross-checked the results with other 
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sources of information (73) such as with experts in RT, I did not systematically validate all 
responses provided by the administrators.  Lastly, the outcome data in this paper were 
drawn from observational studies and are therefore subject to all biases inherent in this type 
of study including selection, confounding and information bias (146-149).  
7.3.3 C-ACS:  A new risk score for early ACS prognostication 
Use of a categorical rather than a continuous scoring system likely decreased the 
precision of the C-ACS score.  However, a categorical system is preferable in emergency 
situations due to its simplicity.  Second, although I could have included more covariates in 
the model to improve its accuracy, I limited the model to four variables to maintain its 
simplicity.  Third, the validity and reliability of the clinical measurements used in the C-
ACS risk score were not ascertained.  Nevertheless, all required clinical measurements are 
easy to obtain and can be rapidly obtained by most health care professionals without 
advanced medical training.   Fourth, the C-ACS risk score is developed and validated in 
studies that included only patients who survived to presentation at the hospital (7-
8,145,182, 186.221).  The prognostic value of this risk score might differ if patients who 
died before reaching the hospital were included. Finally, it remained possible that the 
increased mortality of patients with high C-ACS scores might be also due to different in-
hospital management compared to patients with lower C-ACS scores.  
7.4 Study strengths 
7.4.1 Bayesian meta-analyses comparing primary PCI versus FL in RCTs and 
observational studies 
Our meta-analyses improved on previous systematic reviews by including short-
term results from four recent RCTs (2, 19-21).  I also incorporated events at  1 year, as 
well as longer-term results from five RCTs that were not considered in earlier reviews 
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(i.e., data at 1-year from Dobrycski and PRAGUE-1 (32,90), at 2-years from the PAMI-1 
(91) at 3-years from DANAMI-2 (225), at 5-years from PRAGUE-2 (226) and at 8-years 
from the Zwolle Study (227). Given the marked heterogeneity across RCTs in study 
design and patient populations, the random-effects hierarchical Bayesian approach is 
more appropriate (113-115) than the fixed-effects models used in previous meta-analyses 
(37,92,96-98,101,106).  Bayesian meta-analysis allows studies with small sample sizes to 
contribute more to the overall estimate. Consequently, larger studies (with flaws in study 
design) would have less impact on the global estimate than with other non-Bayesian 
random-effects models (116). 
This study is the first systematic review that incorporates results from observational 
studies that compare the effectiveness of primary PCI and FL. Incorporation of evidence 
from observational studies enhances the external validity of previous meta-analyses (199-
201). The inclusion of several international cohorts of “real-life” STEMI patients 
provides additional global perspectives on reperfusion strategies. Finally, the estimates of 
the numbers needed to treat to save one event in RCTs and observational studies provide 
additional insight to clinicians and policy-makers in terms of selecting the most 
appropriate RT.  
7.4.2 International perspectives on PHL 
Our survey represents the first collaboration between several North American and 
European pre-hospital ACS systems of care (67).  In addition to detailed multinational 
descriptions of the infrastructures and processes for managing patients with STEMI, I also 
reported the outcomes of PHL administered by a variety of health care providers, within 
diverse pre-hospital EMS programs (67).   This study provides unique international 
perspectives on the feasibility, effectiveness and safety of PHL.  Since PHL expedites 
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administration of FL, and decreases the time delay to coronary reperfusion, more 
widespread implementation of PHL may reduce myocardial (heart) damage as well as 
mortality related to STEMI globally.    
7.4.3 C-ACS:  A new risk score for early ACS prognostication 
The validation of the C-ACS risk score in several large datasets of patients with 
STEMI and NSTE-ACS ), across different time periods (EFFECT- 1 was conducted in 
1999, and the other studies were conducted in 2003-2005), geographic locations and 
systems of care (several Canadian provinces and France) and diverse therapeutic strategies 
(more frequent invasive interventions in the AMI-QUEBEC and FAST-MI patients 
(145,182) versus more conservative management of the EFFECT-1 (221), Canada ACS 1 
and 2 (7-8), and Canada GRACE patients (186)) supports its discriminant value and 
external generalizability to ACS patients within diverse contexts. Furthermore, the good 
discriminant validity of the C-ACS risk score in several large datasets suggests that this risk 
score may be applicable in real-life patients, in contrast to other risk scores that were 
validated primarily in RCTs (220). Since it is a simple ordinal scale that incorporates 
indicators that can be easily obtained at the first medical contact, the C-ACS score may 
promote more optimal early management of ACS patients. 
7.5 Impacts of the publications from this doctoral dissertation 
 In this section, I list the main citations and impacts that have emanated to date 
from the manuscripts in this doctoral dissertation. The first manuscript was selected as one 
of “the most important manuscripts, as selected by the editors, published in Circulation and 
the Circulation subspecialty journals, most read manuscripts published on the topic of 
cardiovascular interventions in 2009 and 2010” (230). This manuscript is highlighted as 
one of “the most important manuscripts, as selected by the editors, that have been 
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published in the Circulation portfolio. The studies included in this article represent the 
most noteworthy research in the area of ST-elevation myocardial infarction. (231). The 
manuscript is mentioned as one of the “major scientific work in the field of Interventional 
Cardiology in 2009” by the editors of the Journal of American College of Cardiology 
(232). This manuscript is also cited by the European Society of Cardiology Textbook of 
Intensive and Acute Cardiac Care (232).  Recently, the Ontario Medical Advisory cited this 
manuscript several times in their recommendations on re-organization of care for patients 
with STEMI in Ontario for the year 2010 (111).  
 The second manuscript “The pre-hospital fibrinolysis experience in Europe and 
North America and implications for wider dissemination” was published in JACC 
Cardiovascular Intervention in 2011.  Following its publication, I was contacted by Dr 
Young (i.e., the Health Canada Officer responsible for care in the First Nations) for advice 
concerning the feasibility of implementing PHL in Northern Quebec (234).  
The last manuscript ’C-ACS:  A New Risk Score for Early Prognostication in Acute 
Coronary Syndromes” is currently in press by the American Heart Journal. 
7.6 Future research  
Future research which raises awareness of the importance of timely treatment will 
stimulate interest and efforts to deliver the best care to all patients with ACS. Continuous 
monitoring of treatment delays in prospective registries will enable recognition of the types 
of patients at risk of treatment delays, and systems of care with sub-optimal performance.  
Solutions to delays to RT requires close collaboration between hospitals with and without 
PCI-facilities and pre-hospital systems of care.  Participation in ACS research will facilitate 
and strengthen multi-institutional cooperation.  
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Because of its vast geography, sparsely-populated territories, and inclement winter 
weather, many patients with ACS experience excessive delays to RT in Canada (229).  It is 
critical that EMS health providers strive to improve the care of ACS patients in Canada.  
Since primary PCI within acceptable delays is not possible for all Canadians, it is essential 
that alternate RT strategies such as PHL be implemented, especially for the many 
Canadians living in remote rural areas (202).  Future research should focus on the 
feasibility, effectiveness and safety of PHL in rural regions in Canada.   
Pre-hospital innovations should aim for treatment tailored to the mortality risk of 
individual patients with ACS.  The C-ACS score may be useful for rapid risk stratification 
of patients with ACS, to enable the most appropriate treatment for each individual ACS 
patient. However, the applicability and prognostic value of the C-ACS needs to be 
validated prospectively in the pre-hospital setting.    
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Chapter 8 
Conclusions 
 The findings of this doctoral dissertation make substantial contributions to current 
knowledge in ACS management.  Incorporation of long-term mortality data from recent 
RCTs into the meta-analyses described in the first manuscript supports the survival benefit 
of primary PCI observed in the rigorously controlled conditions of RCTs.  The lack of 
conclusive difference in long-term mortality between primary PCI and FL in observational 
studies, suggests attenuation in the survival benefit of primary PCI in “real-life” STEMI 
patients within “real-life” contexts.  This finding corroborates current international STEMI 
recommendations that FL is an acceptable alternative to primary PCI when primary PCI 
cannot be provided within optimal time delays (79).    
 Although PHL improves survival compared to in-hospital administration of FL, its 
safety and effectiveness have not been well characterized in “real-life” STEMI patients 
outside the RCT context. The pre-hospital infrastructure required for PHL has not been 
adequately studied, so that the comprehensive description of several existing pre-hospital 
systems of care that provide PHL in the second manuscript may assist policy-makers to 
implement PHL and reduce STEMI-related mortality.   
 Finally, in view of the trend towards early use of PCI in patients with ACS, it is 
imperative that health care providers have access to a simple method to risk stratify patients 
with ACS at the time of initial contact.  Early ACS management can then be appropriately 
tailored to the patient’s mortality risk to maximize the benefits and minimize the risks of 
invasive coronary intervention.  The proposed ACS risk score, the C-ACS has the required 
simplicity for use in the early management of patients with ACS. Its benefit in the pre-
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hospital management of ACS patients will need to be demonstrated prospectively in future 
studies. 
 Overall, the three manuscripts in this thesis (66,67,204) address major knowledge 
gaps in ACS care and the findings provide critical and practical knowledge and tools for 
health care providers.  This doctoral dissertation will contribute to making timely and high-
quality ACS care more accessible. 
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Appendix 1. Funnel Plot of short-term mortality 
Randomized controlled studies 
 
The fail-safe N is 51.  This means that we would need to locate and include 51 'null' 
studies in order for the combined 2-tailed p-value to exceed 0.050.   
 
Under the random effects model the point estimate and 95% confidence interval for the 
combined studies is 0.71061 (0.59005, 0.85580).  Using Trim and Fill these values are 
unchanged (blue and red diamonds for original estimate and estimate with Trim and 
Fill, respectively). 
Observational Studies
 
 
The fail-safe N is 212.  This means that we would need to locate and include 212 'null' 
studies in order for the combined 2-tailed p-value to exceed 0.050.   
 
Under the random effects model the point estimate and 95% confidence interval for the 
combined studies is 0.82688 (0.68204, 1.00248).  Using Trim and Fill these values are 
unchanged. 
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APPENDIX 2.  SURVEY ON INTERNATIONAL INFRASTRUCTURE AND 
PROCESS OF PRE-HOSPITAL FIBRINOLYSIS. 
Name of respondent  
Jurisdiction (city/country)  
Date  
 
Question Answers 
1.1   Populations with access 
to pre-hospital fibrinolytic 
therapy  
 
1.2   Names of cities covered 
by this survey  
1.3 Number of hospitals 
involved        
1.4  % of hospitals with 
cardiac cath labs facilities  
1.5  % of rural territories 
covered (rural defined as 
<2,500 population/US 
census ) 
 
xxiii 
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SECTION 2. EXPERTISE OF PRE-HOSPITAL PERSONNLE 
 
Definitions 
ACP: An advanced care paramedic (ambulance technician) with advanced cardiac life 
support training 
PCP: Emergency Medical [paramedic (ambulance technician) without advanced cardiac 
life support training 
 
Question Answers 
2.1 Approximate % of pre-
hospital transports by 
ACPs  
      
2.2 Approximate % of pre-
hospital transports by 
PCPs  
      
2.3  Approximate % of pre-
hospital transports with 
physicians  
 
2.4 Approximate % of pre-
hospital transports with 
nurses 
 
2.5 Other medical or 
paramedical personnel in 
the ambulances 
 
xxiv 
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SECTION 4. PRE-HOSPITAL 12 LEAD ELECTROCARDIOGRAM (ECG) CAPABILITY 
 
Question 
 
Answers 
3.1 Indicate the estimated proportion of all ambulances 
equipped with cardiac monitors with 12 lead ECG 
capability  
      (0-100%) 
 
_______% 
3.2 Indicate the estimated proportion of all paramedics 
able to acquire 12-lead ECG  
      (0-100%) 
______% 
3.3 Indicate the year when 12 lead ECG capability 
began to be routinely used. 
Year:       
3.4 Indicate whether the cardiac monitors routinely 
generate automated interpretations of the 12 lead 
ECGs. 
 Yes 
 
 No 
3.5 Indicate whether the cardiac monitors with 12 lead 
capability include software decision tools for 
reperfusion or fibrinolysis. (e.g., Thrombolysis 
Prediction Instrument [TPI] index)  
 Yes 
 
 No 
*Fibrinolysis/Reperfusion Therapy includes intravenous thrombolysis (eg TNK, tPA, 
streptokinase) and Percutaneous Coronary Intervention (PCI)
xxv 
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SECTION 4: PRE-HOSPITAL 12 LEAD ECG INTERPRETATION 
 
Question 
 
 
4.1 Approximately what proportion of all 
paramedics have training for  
a) direct interpretation of        ECG 
tracings;  
b) interpretation of automated ECG 
messages?    
 
a) Direct interpretation of ECG 
tracings:  
0-100% 
________ 
b) Interpretation of automated ECG 
messages: 
0-100% 
_______ 
4.2 Indicate the year when this training of 
paramedics began. 
 
Select N/A if not applicable. 
a) Direct interpretation of ECG 
tracings: 
Year:  
      
 or  N/A 
 
b) Interpretation of automated ECG 
messages: 
Year:       
or    N/A 
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SECTION 5. PRE-HOSPITAL 12 LEAD ECG TRANSMISSION AND ED 
NOTIFICATION 
 
Definitions 
STEMI: STEMI refers to an ST segment elevation acute myocardial infarction that is 
suspected based on a 12 lead ECG 
ED: Emergency Department 
 
Question 
 
Answers 
5.1 Do the paramedics that acquire 12 lead ECGs 
routinely transmit them (e.g., by modem, cell 
phone, radio, etc.) to the receiving hospital prior to 
their arrival if they suspect an acute STEMI?  
 
 Yes 
 
 No 
5.2 Indicate the year when transmission of 12 lead ECGs 
from ambulance to hospital began. 
Year:       
5.3  Approximate proportions of failures of transmission 
of pre-hospital ECG (0-100%) 
__________________ 
5.4 At the ED, who is the responsible person assigned to 
review the transmitted ECG 
       
 Emergency physician 
 Cardiologist on call 
 Interventional 
cardiologist 
 Nurse 
 Other personnel, please 
specify _________ 
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SECTION 6. PRE-HOSPITAL AMI BYPASS PROTOCOLS 
 
Definitions 
Pre-hospital re-direct agreements: Pre-hospital re-direct agreements refer to the formal 
protocols allowing paramedics to routinely bypass the closest ED(s) and directly transfer 
a suspected or confirmed STEMI patient to a hospital with a cardiac catheterization 
facilities for primary PCI. 
 
Question 
 
Answers 
6.1 Do the operators have formal written medical re-
direct agreements allowing paramedics to bypass the 
closest ED(s) and transport a patient directly to 
hospitals with cardiac catheterization facilities if the 
Paramedics suspect an acute STEMI?  
 
 Yes 
 
 No 
6.2 Indicate the year when these agreements came into 
effect. 
Year:       
6.3 When an acute STEMI is suspected by a 
Paramedic, estimated proportions of patients who 
were re-directed to hospital with PCI capability (0-
100%) 
 
 
 
 
 
____________ 
  
xxviii 
 
xxviii 
 
 
SECTION7. PRE-HOSPITAL FIBRINOLYSIS 
Question Answers 
7.1 Is the pre-hospital fibrinolysis a 
routine part of the pre-hospital 
management of acute STEMIs?  
 
 Yes 
 
 No 
7.2 Is there a fibrinolysis checklist or 
similar decision tool employed as 
routine practice by Paramedics? 
 
 Yes 
 
 No 
7.3  Is there any age exclusion of patients 
from pre-hospital fibrinolytic therapy 
 Yes 
 
 No 
7.4 If yes, please provide the age cut-off ___________ 
7.5 Who decides to initiate pre-hospital 
fibrinolysis 
 Paramedics 
 Physician in the ambulances 
 Emergency physician at the hospital 
 Cardiologist at the hospital 
  
7.6 Medications routinely administered at 
the time of pre-hospital fibrinolysis, 
please check all that apply 
 Aspirin 
 Thienopyridines  
 Anticoagulant, type LWMH ________ 
xxix 
 
xxix 
 
or UFH_______ 
 Beta-blockers 
 Others, please specify ___________ 
7.7   Types of fibrinolytic agents, and 
approximate % used 
 tenecteplase, % used  ________ 
 tissue plasminogen activator,  
     % used  ________ 
 reteplase,. % used  ________ 
 streptokinase, % used  ________ 
 Others, please specify ___________ 
     % used  ________ 
7.8   After successful pre-hospital 
fibrinolysis (defined as complete or 
partial resolution of chest pain, ST 
elevation <90 minutes from 
administration of fibrinolytic therapy, 
are the patients routinely or 
selectively sent to hospitals with 
cardiac cath labs (0-100%)? 
 Routine 
 Selective, if selective, please indicate 
approximate % of patients sent to 
hospitals with cardiac cath labs (0-100%) 
__________ 
7.9   After successful pre-hospital 
fibrinolysis, are the patients routinely 
or selectively sent for <24 hour 
coronary angiogram  
 
 Routine 
 Selective, if selective, please indicate 
approximate % who undergo <24-hour 
coronary angiogram (0-
100%)__________ 
7.10 After successful pre-hospital 
fibrinolysis,  approximate median 
delay between pre-hospital 
fibrinololytic therapy and same-day 
____________ 
xxx 
 
xxx 
 
coronary angiogram 
7.11  After successful pre-hospital 
fibrinolysis,  are patients routinely or 
selectively sent for in-hospital 
coronary angiogram 
 
 Routine 
 Selective, if selective, please indicate 
approximate % of patients who undergo 
in-hospital coronary angiogram (0-
100%)__________ 
7.12  After unsuccessful pre-hospital 
fibrinolysis (defined as lack of ST 
resolution and symptoms at 90 
minute after pre-hospital FL) are the 
patients routinely or selectively sent 
for urgent/rescue  coronary 
angiogram 
 Routine 
 Selective, if selective, please indicate 
approximate % of patients who undergo 
in-hospital coronary angiogram (0-
100%)__________ 
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SECTION 8.  OUTCOMES OF STEMI PATIENTS 
Question Answers 
8.1 Is there systematic collection of in-
hospital outcomes of STEMI patients 
 
 Pre-hospital fibrinolytic therapy 
 
 Primary PCI  
 
 No reperfusion therapy 
8.2 If not systematic collection of in-
hospital outcomes of STEMI 
patients, please estimate % of patients 
with available in-hospital outcomes 
data 
 
_____  Pre-hospital fibrinolytic therapy 
 
______ Primary PCI  
 
______No reperfusion therapy 
8.3 Is there systematic collection of 1-
year outcomes of STEMI patients 
 
 Pre-hospital fibrinolytic therapy 
 
 Primary PCI  
 
 No reperfusion therapy 
8.4 If not systematic collection of in-
hospital outcomes of STEMI patients, 
please estimate % of patients with 
available 1-year outcomes data 
 
_____  Pre-hospital fibrinolytic therapy 
 
______ Primary PCI  
 
______No reperfusion therapy 
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Appendix 3. Predictors of in-hospital mortality in the AMI-QUEBEC dataset 
Univariate models 
Predictors Univariate analysis Multivariate analysis 
OR 
(95% CI) 
p- 
values 
OR 
(95% CI) 
p- 
values 
 
Age 
Female gender 
Diabetes mellitus 
Prior AMI 
Prior PCI 
Prior CABG 
Prior stroke 
Aspirin use 
Initial SBP (mmHg) 
 
Initial HR per minute 
Killip class, for every class 
increase 
 
1.06 (1.04-1.07) 
1.85 (1.21-2.80) 
1.40 (0.82-2.38) 
1.78 (1.14-2.78) 
1.36 (0.83-2.23) 
1.31 (0.56-3.08) 
2.02 (1.05-3.88) 
1.91 (1.34-2.72) 
  0.988  
(0.982-0.995) 
1.02 (1.01-1.03) 
2.32 (1.94-2.78) 
 
<0.001 
 0.004 
 0.221 
 0.011 
 0.219 
 0.539 
 0.034 
<0.001 
<0.001 
 
<0.001 
<0.001 
    
1.63 (1.34-1.97)    
  0.96 (0.59-1.57) 
 
  1.15 (0.69-1.90) 
 
 
  1.01(1.00-1.02) 
1.30 (0.87-1.94) 
  1.10 (0.90-1.22) 
 
1.22 (1.10-1.34) 
1.91 (1.54-2.38) 
               
 
<0.001 
0.28 
 
0.60 
 
 
0.96 
0.20 
0.02  
 
<0.003 
<0.001 
Multivariate model with age, BP, HR and Killip as categorical variables 
Age ≥75 years* 
SBP <100 mmHg 
HR >100 per minute 
 Killip class >1 
3.53 (2.25-5.54) 
2.23 (1.30-2.81) 
1.80 (1.08-2.99) 
3.22 (2.01-5.16) 
<0.001 
0.003 
0.02 
<0.001 
AMI:  Acute Myocardial Infarction,  
CABG:  Coronary Artery Bypass Graft Surgery, 
 CI:  Confidence Intervals,  
xxxiii 
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HR:  Heart Rate 
OR:  Odds Ratios,  
PCI:  Percutaneous Coronary Intervention,  
SBP:  Systolic Blood Pressure 
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Appendix 4. Distribution of the C-AMI risk score in the different datasets 
C-ACS AMI-QUEBEC 
% 
Canada ACS-1 
% 
Canada ACS-2 
% 
Canada-GRACE
% 
EFFECT-1 
% 
FAST-MI 
% 
STEMI 
0 66.4 57.5 NA 54.0 49.0 53.9 
1 20.3 27.9 NA 28.6 29.8 30.5 
2 9.0 11.7 NA 12.5 13.7 12.1 
3 and 4 4.4 3.0 NA 4.9 5.6 3.5 
NSTE-ACS 
0 NA 58.7 56.5 52.3 38.5 40.4 
1 NA 29.6 30.1 32.3 30.1 34.0 
2 NA 9.8 11.4 12.0 20.3 20.4 
3 and 4 NA 1.9 2.0 3.4 9.7 5.2 
ACS: Acute Coronary Syndromes 
AMI:  Acute Myocardial Infarction  
AMI-QUEBEC:  Acute myocardial infarction in Quebec 
EFFECT-1: Enhanced Feedback for Effective Cardiac Treatment 
GRACE (Canada): Global registry of Acute Coronary Events (Canadian subgroup) 
NA:  Non-applicable 
STEMI:  ST-segment Elevation Myocardial Infarction 
FAST-MI:  French registry of Acute ST-elevation and non–ST-elevation Myocardial Infarction 
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Appendix 5.  Subgroup analyses of the C-AMI score in the AMI-QUEBEC study 
 
 
Subgroups of patients 
 
In-Hospital Mortality 
C-statistics 
OR (95% CI) 
 
 
 
Five-Year Mortality 
C-statistics 
OR (95% CI) 
 
≥65 years old 
Diabetics 
Females 
Males 
Heart rate 50-150 per minute 
 
 
0.69 (0.62-0.76) 
0.75 (0.65-0.86) 
0.72 (0.63-0.80) 
0.78 (0.71-0.85) 
0.76 (0.71-0.82) 
 
 
0.69 (0.63-0.85) 
0.81 (0.74-0.89) 
0.75 (0.62-0.81) 
0.74 (0.68-0.81) 
0.77 (0.73-0.81) 
 
C-AMI:  Canada Acute Myocardial Infarction 
OR:  Odds Ratios 
CI:  Confidence Intervals
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